Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
11/2012 | Recent  |  14: Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions November recently filed with US Patent Office 11/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
11/29/2012 > 160 patent applications in 127 patent subcategories. recently filed with US Patent Office

20120302492 - Antibody mimetic scaffolds: Provided herein are protein scaffolds, e.g. antibody mimetic scaffolds, comprising a three finger protein domain that specifically bind to target molecules, polynucleotides encoding such proteins, methods of using such proteins, and libraries of such scaffolds.... Agent: Bayer Healthcare LLC

20120302491 - Modulation of estrogen receptor-related receptor gamma (err gamma) and uses therefor: This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERRγ activity to the subject. Such agents can include one or more ERRγ agonists. In some examples the... Agent: The Salk Institute For Biological Studies

20120302493 - Cyclic peptides as g-protein coupled receptor antagonists: The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages.... Agent: Promics Pty Limited

20120302494 - Synergistic combinations of polyene fungicides and non-ribosomal peptides and related methods of use: The present invention includes compositions comprising a synergistic fungicidal combination of a polyene fungicide and at least one lipopeptide and methods for using such compositions in controlling fungal pathogens.... Agent:

20120302495 - Insecticidal proteins derived from bacillus thuringiensis: The present invention relates to the field of plant pest control, particularly insect control. Provided are nucleotide sequences from Bacillus thuringiensis encoding insecticidal proteins. Further provided are methods and means for using said nucleotide sequence for controlling plant insect pests.... Agent: Bayer Cropscience N.v.

20120302496 - Novel 24-membered cyclooctadepsipeptides from fungal strains and their use as anthelmintics or endoparasiticides: The present invention relates firstly to the discovery of the previously unknown 24-membered cyclooctadepsipeptides PF1022-V, PF1022-W, XRB-C894, XRB-C942, XRB-C976, XRB-C1010, XRB-C1044, XRB-E922, XRB-E956, XRB-E990, XRB-E1024, XRB-S958, XRB-S992, XRB-S1026, XRB-S1060 (in various isomeric forms) and to the processes for the preparation of the abovementioned cyclooctadepsipeptides by means of the fungal strains... Agent: Bayer Intellectual Property Gmbh

20120302497 - Methods of treating medical conditions using calcitonin analogs: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.... Agent: Unigene Laboratories, Inc.

20120302498 - Insulin like peptides: It is described the preparation of Insulin like peptides, of chimeric Insulin like peptides and of their derivatives by the random combination of their chains A and their chains B and the pharmaceutical application of the obtained products.... Agent: Chemical & Biopharmaceutical Laboratories Of Patras Sa

20120302499 - Sterilized, acellular extracellular matrix compositions and methods of making thereof: Methods for sterilizing and decellularizing extracellular matrix materials are disclosed. Extracellular matrix compositions produced using the disclosed methods are also disclosed.... Agent:

20120302500 - Use of somatostatin analogs in meningioma: The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma.... Agent: Novartis Ag

20120302502 - Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion: Compositions and methods are provided for mucosal delivery of peptides. The compositions include a stably hydrated peptide active agent complexed with a crown compound and/or a counter ion solubilized in a non-aqueous hydrophobic vehicle at a pH different from the pI of the peptide active agent. The methods include administering... Agent: Arisgen Sa

20120302501 - Treatment of diabetic cardiomyopathy with a glp-1 peptide: Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines... Agent: Amylin Pharmaceuticals, Inc.

20120302503 - Peptides for preventing or treating a disease or disorder associated with cbp or p300 misregulation, and methods for use and identification thereof: Described herein are therapeutic peptides composed of a cell penetrating peptide, a peptide derived from the sequence of c-Myb, and a peptide derived from the sequence of CREB, useful for the treatment or prevention of a disease or disorder associated with CBP or p300 misregulation.... Agent: Aml Therapeutics, LLC

20120302504 - Method of reducing injury to mammalian cells: A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron is disclosed. The method comprises administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor-neuronal... Agent: Nono, Inc.

20120302505 - Cyclodextrin-based polymers for therapeutic delivery: Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic... Agent:

20120302506 - Maspin-based treatment and prevention of cancer: The present invention provides maspin-related compositions and methods of use thereof. In particular, the present invention provides maspin-related compositions, and methods or use thereof, for the promotion of cell adhesion.... Agent:

20120302507 - Liquid product of botulinum toxin type a: Disclosed are a liquid product of botulinum toxin type A and a method for conserving the potency of botulinum toxin type A using a dextrose solution. Free of a stabilizer, such as albumin or gelatin, the liquid product of botulinum toxin type A completely excludes the possibility of cross infections... Agent:

20120302509 - Compositions and methods to prevent cancer with cupredoxins: The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The present... Agent: The Board Of Trustees Of The University Of Illinois

20120302510 - Histone deacetylases, and uses related thereto: The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell... Agent: President And Fellows Of Harvard College

20120302508 - Sustained-release formulation: The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic acid-glycolic acid copolymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably release compound (I) or a salt... Agent: Takeda Pharmaceutical Company Limited

20120302511 - Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer: Provided are peptides that bind to the thymidylate synthase protein, in particular to human thymidylate synthase (hTS) protein, for the treatment of cancer. Further provided are peptides that can bind at a binding site located at the interface of thymidylate synthase protein. These peptides range from 3 to 10, preferably... Agent:

20120302512 - Isolated laminin-421: The present disclosure provides isolated laminin-421, methods for making recombinant laminin-421, and host cells that express recombinant laminin-421. The present disclosure also provides nucleic acid sequences encoding full length human laminin β2 chain, expression vectors and host cells thereof.... Agent: Biolamina Ab

20120302513 - Mitochondrial function improver: Provided are a mitochondrial function improver, an energy consumption promoter, and a lipid combustion promoter which contain a fat globule membrane component as an active ingredient.... Agent: Kao Corporation

20120302514 - Glycoconjugates and methods: Disclosed are compositions containing glycoconjugates and methods for making the functionalized glycoconjugates, which include (a) contacting a cell with a first monosaccharide, and (b) incubating the cell under conditions whereby the cell (i) internalizes the first monosaccharide, (ii) biochemically processes the first monosaccharide into a second saccharide, (iii) conjugates the... Agent:

20120302515 - Methods for producing phytoextracts from vegetation waters and olive oil pomaces and compositions obtained thereby: Methods are provided for obtaining phytoextracts from vegetation waters and pomaces coming from olive milling. Such methods may be based on combining physical-chemical and enzymatic pre-treatment methods, membrane tangential filtration and vacuum evaporation. Such methods allow eco-sustainable and efficient extraction of the active ingredients involved. Compositions resulting from such methods... Agent: Phenofarm S.r.l.

20120302516 - Nanoparticles for drug delivery: The invention provides magnetic nanoparticles comprising a core, wherein the nanoparticles comprise at least one therapeutic agent linked to the core via a hydrazone linkage or via an oxime ether linkage, methods for making said nanoparticles, and methods for using said nanoparticles.... Agent: University Of Louisville Research Foundation, Inc.

20120302517 - Tet2 as a new diagnostic and pronostic marker in hematopoietic neoplasms: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene... Agent: Institut Gustave-roussy

20120302624 - Biomarker for identifying subgroup of early-stage lung adenocarcinoma patients: The preset invention relates to a biomarker for identifying the subgroup of early-stage lung adenocarcinoma patients in early-stage non-small cell lung cancer (NSCLC), which is T-lymphokine-activated killer cell-originated protein kinase (TOPK), and a therapeutic target for lung cancer.... Agent:

20120302622 - Conjugates, particles, compositions, and related methods: Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions.... Agent: Cerulean Pharma Inc.

20120302626 - Microrna and use thereof in identification of b cell malignancies: Disclosed are nucleic acid sequences, including microRNA sequences and cDNA sequences, as well as vectors, DNA libraries, microarrays, and recombinant cells comprising the nucleic acid sequences described herein. Methods of determining the B cell stage from which a B cell malignancy is derived. Methods of identifying B cell malignancies are... Agent:

20120302623 - Novel activation and transfer cascade for ubiquitin: A novel activating enzyme for ubiquitin, Uba6, is provided. Compositions and methods for inhibiting ubiquitin via the Uba6 pathway are provided. Methods of identifying novel inhibitors of ubiquitination are also provided. Novel RNAi molecules are also provided.... Agent: President And Fellows Of Harvard College

20120302625 - Supercoiled minicircle dna for gene therapy applications: The present invention relates to nucleic acid molecule compositions comprising minivectors encoding a nucleic acid sequence and methods of gene therapy using minivectors encoding a nucleic acid sequence.... Agent: Baylor College Of Medicine

20120302627 - Method of using adenoviral vectors to induce an immune response: The invention provides a method of inducing an immune response against a human immunodeficiency virus (HIV) in a mammal. The method comprises administering to the mammal an adenoviral vector composition comprising one or more adenoviral vectors encoding two or more different HIV antigens, the production of which induces an immune... Agent: Genvec, Inc.

20120302628 - Oligonucleotides which inhibit p53 induction in response to cellular stress: The present invention relates to novel oligonucleotides which comprise p53 5′-UTR sequence TCCCTGG (SEQ ID NO: 1) or the complementary p53 3′-UTR sequence CCAGGGA (SEQ ID NO: 2) and their use for such therapeutic applications as protection of normal tissues from the toxicities of chemical or radiation exposure; reducing tissue... Agent: St. Jude Children's Research Hospital

20120302518 - Polymorphic form of n-(s)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof: Disclosed herein, in certain embodiments, is a crystalline polymorph form A of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. Further disclosed herein, in certain embodiments, are pharmaceutical compositions comprising the crystalline polymorph form A of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.... Agent: Ardea Biosciences, Inc.

20120302519 - Multiple substituted fluoromethanes as selective and bioactive isosteres: Disclosed herein are substituted fluoromethanes; pharmaceutical compositions comprising a therapeutically effective amount of the same; processes for preparing these fluoromethanes; and methods of using the same in alleviating infection and parasitism. Also disclosed are methods for identifying substituted fluoromethanes for modulating the activity of receptors and enzymes that bind and/or... Agent: Meh Associates, Inc.

20120302520 - Gemcitabine combination therapy: The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.... Agent: Celgene Corporation

20120302521 - Inhibition of pancreatic lipase: The present invention provides the use of an alginate Io inhibit pancreatic lipase. The use may be directed to the control of weight in animals including human beings. Preferably the fraction of guluronate dimers in the alginate is at least 0.5.... Agent: Rd Biomed Limited

20120302522 - Synergistic antiviral composition and use thereof: The present invention relates to iota- and/or kappa-carrageenan in combination with a neuraminidase inhibitor for use as a medicament in the prophylactic or therapeutic treatment of a symptom, condition or disease caused by or associated with an infection by an influenza virus.... Agent: Marinomed Biotechnologie Gmbh

20120302524 - 1,3,4-oxadiazole-2-carboxamide compound: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the... Agent: Shizuoka Prefecture

20120302523 - Endoperoxides and methods of photocatalytically synthesizing endoperoxides: R1 is an aryl substituted with at least one group selected from the group consisting of alkoxy, hydroxyl, halogen, carbamate, sulfonamide, silyloxy, amide, and combinations thereof or a substituted or unsubstituted heteroaryl, R2 is hydrogen, alkyl, alkynyl, or aryl, R3 is hydrogen, alkyl, alkynyl, or aryl, R4 is alkynyl or... Agent: Wisconsin Alumni Research Foundation

20120302525 - Synthetic bile acid compositions and methods: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.... Agent: Kythera Biopharmaceuticals, Inc.

20120302527 - C7-fluoro substituted tetracycline compounds: l

20120302526 - Methods for treating post-traumatic stress disorder: Provided herein are methods for treating negative effects of traumatic brain injury (TBI), post traumatic stress disorder (PTSD), or acute stress disorder (ASD). These methods comprise administration of an effective amount of ibudilast to a subject suffering from TBI, PTSD, or ASD.... Agent: Regents Of The University Of Colorado, A Body Corporate

20120302528 - Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about... Agent: Ethicon, Inc.

20120302529 - Method of treating actinic keratosis and basal cell carcinoma: A method for treating actinic keratosis or basal cell carcinoma. A person's skin is inspected to identify areas that exhibit lesions indicating actinic keratosis or basel cell carcinoma. If such areas are found, a treating composition is applied to the skin in that area. The treating composition may include avobenzone,... Agent:

20120302530 - 23-hydroxy-betulinic acid derivatives, preparation methods and uses thereof: The present invention discloses 23-hydroxyl-betulinic acid derivatives, including 3-oxo-23-hydroxyl-betulinic acid, 3-oxo-23-hydroxyl-dihydrobetulinic acid, and 23-hydroxyl-dihydrobetulinic acid. The present invention also discloses the preparation methods thereof and medical applications as anti-tumor and anti-HIV agents.... Agent: Suzhou Maidixian Pharmaceutical Inc.

20120302531 - Beta-2-adrenoreceptor agonists: e

20120302532 - Combinations comprising antimuscarinic agents and corticosteroids: Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic... Agent:

20120302533 - Derivatives of pyrimido [6,1-a] isoquinolin-4-one: The present invention relates to derivatives of pyrimido[6,1-a]isoquinolin-4-one and their application as inhibitors of phosphodiesterase (PDE) isoenzymes. More particularly the invention relates to derivatives of pyrimido[6,1-a]isoquinolin-4-one and their use in medicine for example as bronchodilators with anti-inflammatory properties.... Agent: Verona Pharma PLC

20120302534 - Derivatives of betulin: e

20120302535 - Progesterone treatment for improving sleep quality: Described herein are therapeutic methods using progesterone and progesterone analogs to improve sleep quality. The methods may be particularly useful to treat subject with perturbed sleep patterns, such as subjects who suffer from mid-sleep period awakenings.... Agent: Besins Healthcare Luxembourg Sarl

20120302536 - Use of dhea derivatives for enhancing physical performance: A method is disclosed for administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof for one of decreasing body weight, reducing adipose tissue, increasing endurance, as an anti-aging compound and generating production of red blood cells.... Agent: Proprietary Wellness, LLC

20120302537 - Treatment methods using pharmaceutical solid state forms: The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state... Agent: Harbor Therapeutics, Inc.

20120302538 - Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections: Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/ and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this... Agent: Achillion Pharmaceuticals, Inc

20120302539 - Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof: Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described.... Agent:

20120302540 - 3-spirocyclic piperidine derivatives as ghrelin receptor agonists: r

20120302542 - Monobactams: The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.... Agent: Pfizer Inc

20120302543 - Compounds for the treatment of neurological disorders: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of certain neurologic disorders, including disorders related to NMDA receptor activation, neuropsychiatric disorders, neurodegenerative disorders and other neurologic diseases, disorders and related conditions. The compounds are of the Formulas I and Ia-Ij as described herein.... Agent:

20120302545 - Method of using pi3k and mek modulators: The invention provides methods of treating cancer with a combination of compounds which inhibit kinases, more specifically MEK and PI3K.... Agent: Exelixis, Inc.

20120302544 - Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators: methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to... Agent:

20120302546 - Novel sulfamides exhibiting neuroprotective action and methods for use thereof: Pharmaceutical compositions of the invention include sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, and any neurodegenerative disease involving glutamate toxicity.... Agent: Advanced Neural Dynamics, Inc.

20120302541 - 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators: a

20120302547 - Novel mch receptor antagonists: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I) wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.... Agent: Eli Lilly And Company

20120302548 - 2-arylimidazole derivatives as pde10a enzyme inhibitors: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present... Agent: H. Lundbeck A/s

20120302549 - Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors: i

20120302550 - Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one: The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.... Agent: Pfizer Inc.

20120302551 - Thiolactams and uses thereof: e

20120302552 - S-mirtazapine for the treatment of hot flush: The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush.... Agent: N. V. Organon

20120302553 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors: e

20120302554 - Phantom phenomena treatment: The present invention relates to a substance for the treatment of the phantom phenomena of tinnitus and/or phantom pain, a method for the diagnosis and for the treatment of these phantom phenomena.... Agent: Auris Medical Ag

20120302555 - Method of treatment using eprosartan: The disclosed invention relates to a method of treatment of a disorder modulated by blocking angiotensin II (AII) receptors, and particularly selected from the group consisting of hypertension, congestive heart failure, renal failure, and combinations thereof, by administering to a subject in need thereof an effective dose of an eprosartan... Agent:

20120302556 - Antiviral compounds: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.... Agent: Prosetta Antiviral Inc.

20120302557 - Biologically active methylene blue derivatives: m

20120302558 - Oxazine derivatives and their use in the treatment of neurological disorders:

20120302559 - Method for treating fungal infections, fungicidal compositions and their use: A fungicidal composition and a method for treating plants using the composition are provided. The composition comprises at least three active ingredient components (A), (B) and (C), optionally together with one or more customary formulation auxiliaries, wherein component (A) is one or more triazole fungicides, component (B) is one or... Agent: Rotam Agrochem International Co., Ltd.

20120302560 - Novel benzoic pyrrolopyridine derivatives: f

20120302561 - Compounds, formulations, and methods of protein kinase c inhibition: The invention provides a method of inhibiting atypical protein kinase C (aPKC) comprising contacting an aPKC with a compound having a structure selected from the group consisting of structural formulas (I) to (IX). The invention further provides a method of inhibiting or reducing vascular permeability. The method comprising administering to... Agent: The Regents Of The University Of Michigan

20120302562 - 4h-thieno[3,2-c]chromene-based inhibitors of notum pectinacetylesterase and methods of their use: Compounds that may be used to inhibit Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting bone.... Agent:

20120302563 - Substituted norindenoisoquinolines, syntheses thereof, and methods of use: Described herein are substituted norindenoisoquinoline compounds, and pharmaceutical compositions and formulations comprising the norindenoisoquinoline compounds. Also described herein are methods for using the compounds for the treatment and/or prevention of topoisomerase mediated diseases, such as cancer.... Agent: Purdue Research Foundation

20120302564 - (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases: The invention relates to (1,2,4)triazolo[4,3-a]quinoxaline derivatives which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases.... Agent:

20120302565 - Kinase inhibitors for preventing or treating pathogen infection and method of use thereof: The present invention provides compositions and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and/or treat... Agent: Emory University

20120302566 - Indanyloxydihydrobenzofuranylacetic acids: wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in... Agent: Boehringer Ingelheim International Gmbh

20120302567 - Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase: The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.... Agent: Hanmi Pharm. Co. Ltd.

20120302568 - Sigma ligands for use in the prevention and/or treatment of post-operative pain: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia,... Agent:

20120302569 - Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation: This invention relates to phenyl thiazole I and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.... Agent:

20120302571 - Crystalline forms of (s)-1-(4-(5-cyclopropyl-1h-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-n-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide: Crystalline forms of (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide of the formula (I) are provided. Also provided is a pharmaceutical composition comprising one or more crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol, as well as a method of using one or more crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol in the treatment of cancer and other proliferative diseases.... Agent: Bristol-myers Squibb Company

20120302570 - Heterocyclic oxime compounds: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for... Agent: Novartis Ag

20120302575 - Methods for preventing oxidative stress injury of a tissue by a folate-tempol conjugate.: The present disclosure is generally related to methods of preventing oxidative stress injury induced by renal is-chemia-reperfusion by a Folate-TEMPOL conjugate.... Agent: Emory University

20120302573 - Methods of inhibiting pro matrix metalloproteinase activation: This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated... Agent:

20120302574 - Methods of preventing and reducing the severity of stress-associated conditions: The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to... Agent: Allergan, Inc.

20120302572 - Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment: The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer... Agent: Osi Pharmaceuticals, LLC

20120302576 - Ampk modulators: e

20120302577 - Treatment of gist with masitinib: The present invention relates to the use of masitinib or a pharmaceutically acceptable salt thereof, and in particular of masitinib mesylate, for the preparation of a medicament for the treatment of GIST, to the use of this therapy for the treatment of GIST, and a method of treating mammals, including... Agent: Ab Science

20120302578 - Aminooxazole inhibitors of cyclin dependent kinases: Oxazole derivatives are described. The inventive compounds are useful as kinase inhibitors, and may be used in the treatment of cancer, such as prostate cancer, lung cancer, breast cancer, colon cancer, leukemia, CNS cancer, melanoma, ovarian cancer, and renal cancer.... Agent: Neosome Life Sciences, LLC

20120302580 - Optically active compound of prulifloxacin for treating infection and preparation method thereof: Anti-infection levorotatory optically active compound (S-configuration) of prulifloxacin represented by the following formula (1) and preparation method thereof are disclosed. Said method utilizes levorotatory ulifloxacin as the raw material and the reaction is conducted in organic solvent in the presence of alkaline materials, wherein the reaction temperature is −20° C.˜60°... Agent:

20120302581 - Methods and compositions for the treatment of ras associated disorders: The instant disclosure relates to compositions that may be useful as therapeutic agents for the treatment of disorders associated or caused by Ras deregulation or dysregulation, for example, disorders associated with alterations in the NF1 gene such as neurofibromatosis type I, fungal infections such as those caused by Candida albicans,... Agent:

20120302582 - Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer: This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-I) that simultaneously damage DNA, and... Agent:

20120302579 - Cancer treatment method: Invented is a method of treating cancer and pre-cancerous syndromes in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.... Agent: Glaxosmithkline LLC

20120302583 - New compounds i: v

20120302584 - Novel salts forms of pyrimidin-5-yl acetic acid derivative: Provided are crystalline N-methyl-glucamine and sodium salts of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl] acetic acid, processes for their preparation, pharmaceutical compositions comprising the salts, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.... Agent: Boehringer Ingelheim International Gmbh

20120302585 - Inhibitors of fatty acid uptake and methods of use: The present disclosure describes inhibitors of fatty acid uptake and methods of using such inhibitors. Specifically, the present disclosure describes inhibitors with specificity for FATP2.... Agent: Nutech Ventures, A Nebraska Corporation

20120302586 - Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase: e

20120302587 - Rho-kinase inhibitors: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.... Agent:

20120302588 - Method of enhancing hair growth: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include bimatoprost and minoxidil in a vehicle for topical application to the skin of a mammal, e.g. a human, whereby the combination of bimatoprost and minoxidil produces a faster onset of hair growth in humans or... Agent:

20120302589 - Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same: The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.... Agent: Amarin Pharma, Inc.

20120302590 - Methods and compositions to prevent addiction: Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject comprising, administering a therapeutic amount of the neurological stimulant and administering an antagonist of the kappa opioid receptor, to thereby reduce or prevent the development of aversion to the CNS... Agent: The General Hospital Corporation

20120302591 - Methods of using 8-carboxamido-2,6-methano-3-benzazocines: s

20120302592 - Topiramate plus naltrexone for the treatment of addictive disorders: The present invention provides for the use of combinations of drugs to treat addictive disorders.... Agent: University Of Virginia Patent Foundation

20120302593 - Use of at least one isoquinoline compound of formula i, pharmaceutical composition for treating or preventing neurodegenerative diseases and method for treating or preventing neurodegenerative diseases: e

20120302594 - Quaternary opioid carboxamides:

20120302595 - Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction: The invention relates generally to neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease). The invention describes AND INCLUDES a direct interaction between proteins FKBP52 and Tau. More particularly, the invention relates to a method for screening a drug for the prevention and treatment of neurological disorders... Agent: Inserm

20120302596 - Azaindoles having serotonin receptor affinity: e

20120302597 - Novel p2x7r antagonists and their use: The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.... Agent: Affectis Pharmaceuticals Ag

20120302598 - Imidazopyridinones: e

20120302599 - Kat ll inhibitors:

20120302600 - Stable laquinimod preparations: The invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable salt of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier.... Agent: Teva Pharmaceutical Industries, Ltd.

20120302601 - Compositions and methods for the treatment of macular degeneration: The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic... Agent: Neuron Systems, Inc.

20120302602 - Vanilloid receptor ligand compounds, pharmaceutical compositions containing them, a method of producing them and the use thereof to treat pain and various other conditions: e

20120302603 - Amyloid binding agents: There are provided compounds and methods for the detection and treatment of amyloid deposits and diseases and disorders characterized by amyloid deposits including Alzheimer's disease and related amyloid-based neurodegenerative disorders.... Agent: The Regents Of The University Of California

20120302604 - Modulation of phospholipase d for the treatment of the acute and chronic effects of ethanol: The present invention relates to methods of decreasing the negative effects of alcohol on behavior as well as inhibiting the toxic effects of alcohol, comprising administering, to a subject, an effective amount of an inhibitor of phospholipase D.... Agent:

20120302605 - 3-deutero-pomalidomide: The present application describes 3′-deutero-pomalidomide, deuterated derivatives thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Deuteria Pharmaceuticals, LLC

20120302606 - 3-(4-((1h-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators: Substituted 3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-phenyl-1,2,4-oxadiazole derivatives which are useful as sphingosine-1-phosphate modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120302607 - C4-substituted alpha-keto oxazoles: The invention provides a series of C4-substituted oxazole compounds having an alpha keto side chain at the 2 position, for example, compounds of formula I. The compounds can inhibit fatty acid amide hydrolase and can be useful for treatment of malconditions modulated by fatty acid amide hydrolase. The invention further... Agent: The Scripps Research Institute

20120302608 - Novel imidazole derivatives useful for the treatment of arthritis: e

20120302609 - Pyrazolines for the modulation of pkm2: The invention relates to pyrazoline substituted compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.... Agent: Dynamix Pharmaceuticals Ltd.

20120302610 - Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists: The present invention is directed to picolanmido-propanoic acid derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.... Agent:

20120302611 - Pesticidal compositions and related methods: Pesticidal compositions that improve soil residual efficacy of sulfoxaflor are disclosed.... Agent: Dow Agrosciences LLC

20120302612 - Novel thiazolidin-4-one derivatives: The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.... Agent:

20120302613 - Novel antibiotics: The invention relates generally to novel antibiotics and their analogs, to processes for the preparation of these novel antibiotics, to pharmaceutical compositions comprising the novel antibiotics; and to methods of using the novel antibiotics to treat or inhibit various disorders.... Agent: Novobiotic Pharmaceuticals LLC

20120302614 - Method for improving cerebral circulation or treating a cerebral blood flow disorder: A method for improving cerebral circulation or treating a cerebral blood flow disorder, comprising administering a pharmacologically effective amount of an angiotensin II receptor blocker to a human.... Agent: Daiichi Sankyo Company, Limited

20120302615 - Method of treatment of cns disorders: The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity.... Agent: Supemus Pharmaceuticals., Inc.

20120302616 - Method of treatment of obsessive compulsive disorder with ondansetron: Methods for treating obsessions and/or compulsions are described. In one method, ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessions and/or compulsions for more than seven days. The ondansetron or pharmaceutically acceptable salt thereof may be administered as a pharmaceutically effective dose up to... Agent:

20120302617 - Phenyl and benzodioxinyl substituted indazoles derivatives: t

20120302618 - Use of benzydamine in the treatment of p40-dependent diseases: Use of benzydamine in the treatment of inflammatory diseases, in particular Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and psoriasis, caused by an expression or overexpression of the cytokine subunit p40.... Agent: Aziende Chim. Riun. Ang. Franc. A.c.r.a.f. S.p.a.

20120302619 - Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.... Agent:

20120302620 - Novel pyrone-indole derivatives and process for their preparation: e

20120302621 - D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders: The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function.... Agent:

20120302629 - Biomarkers for gossypol chemotherapy and methods of treating disease: The present invention provides a biomarker for selecting a patient for treatment with gossypol, wherein the biomarker comprises an elevated expression level of c-Myc, Mcl-1, or combination thereof, relative to the normal expression level of c-Myc, Mcl-1, or combination thereof. The present invention also provides methods for targeting patients for... Agent: The Regents Of The University Of Michigan

20120302630 - Na/k-atpase ligands, ouabain antagonists, assays and uses thereof: Na/K-ATPase/Src ligands, assays and uses thereof are disclosed.... Agent: University Of Toledo

20120302631 - Inhibitors of pfkfb3 for cancer therapy: Compounds used to inhibit glycolytic pathway small molecule kinase 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase (PFKFB) are set forth; these inhibitors can be used in the treatment of certain diseases in which cells or tumors rely on glycolytic metabolism, such as many cancer cells.... Agent:

20120302632 - Dietary control of arachidonic acid metabolism: Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of Δ5 desaturase, and optionally stearidonic acid or ω-3 arachidonic acid. Preferred formulations may be in the form of a good tasting,.preferably milk or fruit based drink, or a dried powder. Compositions... Agent: Wake Forest University

20120302633 - Novel polymorph of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphthalenyl) ester: Herein described is a novel crystalline form of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphtalenyl) ester. In particular, herein described is a polymorph of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphtalenyl) ester, characterized by a Powder X Ray Diffraction spectrum as indicated in FIG. 1, and/or by a... Agent: Chemi Spa

20120302634 - Skin protection compositions, in particular cream to protect against cold: r

20120302635 - Water-swellable polymers: A water-swellable linear polyurethane polymer is formed by reacting a polyethylene oxide (e.g. PEG 4000 to 35,000), a difunctional compound (e.g. a diamine or diol such as 1,10-decanediol) with a diisocyanate. The ratio of the three components is generally in the range 0.1-1.5 to 1 to 1.1-2.5. The polyurethane is... Agent: Ferring B.v.

20120302636 - Method of treating a disorder associated with mtp: or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to a subject that has or is at risk of having a disorder selected from the group consisting of hyperlipidemia, arteriosclerosis, coronary artery diseases, metabolic syndrome, obesity, diabetes, prediabetes, and hypertension, whereupon the disorder is treated or prevented in the subject.... Agent:

20120302637 - Methods of treating tachycardia and/or controlling heart rate while minimizing and/or controlling hypotension: A method of treating tachycardia while minimizing and/or controlling hypotension associated with such treatment includes administering a therapeutically effective amount of a pharmaceutical composition comprising the S-isomer of esmolol to a subject in need thereof.... Agent: Baxter International Inc.

20120302638 - Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids and preparation thereof: Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids were prepared chemically and/or enzymatically. Depending upon the ester, improved melanocyte cytotoxicity was achieved. Improved cytotoxicity characteristics are consistent with ester analogs being more physiologically compatible and less irritating to skin than their corresponding acids.... Agent: Eastman Chemical Company

20120302639 - Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death: A formulation for treating omega-3 fatty acid deficiency is disclosed containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum... Agent: Pivotal Therapeutics Inc.

20120302640 - Oral formulations: The invention relates to a composition, in the form of a gel, comprising tranexamic acid for topical oral application to a tooth extraction site either before, during or after the tooth extraction to control dental bleeding, to treat or prevent alveolar osteitis, or to produce or maintain a blood clot.... Agent:

20120302641 - Biphenyl derivatives useful as glucagon receptor antagonists: The present invention is directed to biphenyl derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.... Agent:

20120302642 - Viscous acidic abrasive cleaning compositions: Aqueous acidic, abrasive hard surface cleaning composition comprising: about 0.5-3.5% wt. of a thickener system which includes both a colloid forming clay, preferably a montmorillonite clay, and a gum based thickener, preferably xantham gum; about 0.01-2.5% wt. of a surfactant selected from anionic surfactants, nonionic surfactants, and mixtures thereof; an... Agent: Reckitt Benckiser LLC

20120302643 - Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride: A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.... Agent: Gruenenthal Gmbh

20120302644 - Adhesive patch for treatment of tinea unguium: The present invention provides an adhesive patch for the treatment of tinea unguium intended to be applied once a day, comprising terbinafine and/or a pharmacologically acceptable salt thereof in an amount of 3 mg/cm2, wherein the adhesive patch is used so that the terbinafine concentration in nails may be 295±127... Agent: Hisamitsu Pharmaceutical Co., Inc.

20120302645 - Use of hydroxytyrosol for improving muscle differentiation: The use of hydroxytyrosol or an olive juice extract containing hydroxytyrosol for improving muscle differentiation and thus improving or maintaining the body's adaptation to exercise is disclosed. The pharmaceutical and nutraceutical compositions comprising hydroxytyrosol useful for conditions characterized by altered muscle differentiation especially under inflammatory conditions, such as delayed onset... Agent:

20120302647 - Synthesis of magnolol and its analogue compounds: A method is described for producing magnolol, or a derivative or analogue thereof. The method includes obtaining MOM ether of 5,5′-diallylbiphenyl-2,2′-diol or a derivative or analogue thereof and subsequently converting the MOM ether of 5,5′-diallylbiphenyl-2,2′-diol into magnolol or a derivative or analogue thereof.... Agent: Colgate-palmolive Company

20120302646 - Use of cannabidiol in the treatment of hepatitis: Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune systems mediating a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind CB1 are also psychoactive thereby limiting their clinical use. Cannabidiol (CBD) is the most abundant nonpsychotropic plant cannabinoid but has... Agent: University Of South Carolina

20120302648 - Implant material and a method for producing same: The invention relates to an implant material comprising a polymer which is partially cross-linked by means of a metal salt.... Agent: Aap Biomaterials Gmbh

20120302650 - Insulin-like growth factor 1 receptor (igf1r) protein srm/mrm assay: The current disclosure provides for specific peptides from the Insulin-Like Growth Factor 1 Receptor (IGF-1R) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying the IGF-1R directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological... Agent: Expression Pathology, Inc.

20120302649 - Method for screening ameliorants of dry skin caused by atopic dermatitis using bleomycin hydrolase activity as indicator: The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison... Agent: Shiseido Company, Ltd.

  
11/22/2012 > 159 patent applications in 114 patent subcategories. recently filed with US Patent Office

20120295832 - Novel lipids and compositions for intracellular delivery of biologically active compounds: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.... Agent: Arrowhead Research Corporation

20120295833 - Polysaccharides having an adjustable degree of functionalization: in which: the polysaccharide may be either, synthetic or modified, i represents the degree of functionalization of the hydroxyls, j represents the degree of functionalization of the hydroxyls, L and Q represent an optionally branched and/or unsaturated chain comprising from 1 to 15 carbons, F is a functional group chosen... Agent: Adocia

20120295834 - Opioid prodrugs with heterocyclic linkers: The embodiments provide prodrug compounds of Formulae I-XV. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XV that provides controlled release of an opioid. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that... Agent:

20120295836 - Glp-i agonist and cardiovascular complications: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.... Agent: Novo Nordisk A/s

20120295835 - Sgef controls macular, corpus callosum and hippocampal function and development, liver homeostasis, functions of the immune system, fever response atherosclerosis and tumorogenic cell growth: The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system or feverless response to infection. Methods of diagnosis of such disease and development... Agent:

20120295837 - Novel antimicrobial agents: A novel class of antimicrobial polymeric agents, which include a plurality of amino acid residues, such as positively charged amino acid residues, and at least one hydrophobic residue linking therebetween, such as an omega-amino-fatty acid residue, designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance... Agent: Technion Research & Development Foundation Ltd.

20120295838 - Selective poly-substituted glycine antibiotics and related compositions: Antimicrobial peptoid compounds and related compositions as can be used against bacteria effectively and selectively.... Agent:

20120295839 - Method of treatment and prophylaxis of bacterial vaginosis: Methods of treatment or prophylaxis of bacterial vaginosis, prevention of recurrence of bacterial vaginosis and alleviation or prevention of symptoms or diagnostic criteria of bacterial vaginosis are provided. The methods include administration of an effective amount of a macromolecule comprising a polylysine, polyamidoamine, poly(etherhydroxyamine) or poly(propyleneimine) dendrimer and one or... Agent: Starpharma Pty Limited

20120295840 - Treatment of aspergillus infections with alpha thymosin peptides: A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.... Agent: Sciclone Pharmaceuticals, Inc.

20120295841 - Sanglifehrin based compounds: m

20120295843 - Combination therapy for the treatment of hcv infection: The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present... Agent: Vertex Pharmaceuticals Incorporated

20120295842 - Phenanthridine macrocyclic hepatitis c serine protease inhibitors: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs... Agent:

20120295844 - Use of aprotinin for treating parasitic infections and prognosing bovine trypanotolerance: The present invention relates the use of aprotinin in the treatment of parasitic diseases or infections that affect domesticated mammals, in particular the cattle, especially bovines. In particular, aprotinin finds application in the fight against pathogenic effects induced by parasites in the Trypanosomatidae family, such as the protozoa that belong... Agent: Institut De Recherche Pour Le Developpement (ird)

20120295845 - Imidazo-pyrazoles as gpr119 inhibitors: Compounds of formula (I) wherein: X is (A) or (B); Y is O or a bond; R1 is —C(O)—O—R3 or R2 is hydrogen, cyano, C1-C6 alkyl, or C3-C6 cycloalkyl; R5 is hydrogen, cyano, nitro, C1-C6 fluoroalkyl, C1-C6 alkyl, C1-C6 alkoxy, fluoroalkoxy, or C3-C6 cycloalkyl; R6 is hydrogen, C1-C6 alkyl, C3-C6... Agent: Pfizer Inc

20120295846 - Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate.... Agent: Sanofi-aventis Deutschland Gmbh

20120295847 - Acylated glp-1 compounds: Protracted GLP-1 compounds and therapeutic uses thereof.... Agent: Novo Nordisk A/s

20120295848 - Sustained-release composition and process for producing the same: Present invention is to provide a sustained-release composition which contains a physiologically active substance in high content even when gelatin is not included, and suppresses its initial excessive release and, thus, can achieve a stable release rate over about one month. A sustained-release composition containing a lactic acid-glycolic acid polymer... Agent: Takeda Pharmaceutical Company Limited

20120295850 - Glp-1 receptor agonists to treat pancreatitis: The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.... Agent: Amylin Pharmaceuticals, Inc.

20120295849 - Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders: The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders.... Agent: Cedars- Sinai Medical Center

20120295851 - Peptides, compositions and uses thereof: Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth... Agent: The Queen's University Of Belfast

20120295852 - Methods of treating depression and other related diseases: The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist.... Agent:

20120295853 - Neuronal pain pathway: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity... Agent:

20120295854 - Methods of inducing tissue regeneration: Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from... Agent:

20120295855 - Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug: The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug.... Agent: Max International, LLC

20120295856 - Fredericamycin derivatives: The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially cancer diseases.... Agent: Zentopharm Gmbh

20120295857 - Extract obtained by a commercially viable process for the extraction of furostanolic saponins from fenugreek seeds, in which one of the compounds in the extract is protodioscin: Disclosed is an extract obtained by a commercially viable process for the extraction of furostanolic saponins from fenugreek seeds, in which one of the compounds in the extract is protodioscin. The process includes providing plurality of fenugreek seeds and crushing the same by milling and grinding; performing a primary extraction... Agent:

20120295858 - Use of danshensu, notoginsenoside r1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder: The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder.... Agent:

20120295859 - Method for treatment of malaria: A method for treatment of malaria including administering to a patient in need thereof a flavonoid glycoside compound.... Agent: The Second Military Medical University

20120295860 - Organic compounds: Compounds of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B) inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further... Agent:

20120295861 - Combination therapy with organic arsenicals: The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-I in combination with another therapeutic agent. Another aspect of... Agent: Ziopharm Oncology, Inc.

20120295951 - Genetic changes in atm and atr/chek1 as prognostic indicators in cancer: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to... Agent:

20120295949 - Microrna-based methods and compositions for the diagnosis, prognosis and treatment of tumor involving chromosomal rearrangements: Provided are novel methods and compositions for the diagnosis, prognosis and treatment of tumor involving a chromosomal rearrangement, in particular a tumor or neoplasia of the thyroid gland. In addition, methods of identifying anti-tumor agents are described.... Agent: Qiagen Gmbh

20120295958 - Modulation of glucagon receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.... Agent: Isis Pharmaceuticals, Inc.

20120295956 - Prevention of tissue ischemia and related methods: Provided herein are methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47... Agent: The U.s.a., As Represented By The Secretary, Dept. Of Health & Human Services

20120295957 - Prevention of tissue ischemia and related compositions: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services

20120295950 - Rbp4 in insulin sensitivity/resistance, diabetes, and obesity: Methods for screening molecules that modulate the activity of Retinol Binding Protein 4 (RBP4) and their use in treatment of insulin resistance are described. Also described are methods of diagnosing insulin resistance and related conditions by detecting modulation of RBP4 activity.... Agent: Beth Israel Deaconess Medical Center, Inc.

20120295955 - Rna antagonist compounds for the modulation of her3: The invention relates to oligomer compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions... Agent: Enzon Pharmaceuticals, Inc.

20120295952 - Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity: The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders... Agent: Curna, Inc.

20120295954 - Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon Regulatory Factor 8 (IRF8), in particular, by targeting natural antisense polynucleotides of Interferon Regulatory Factor 8 (IRF8). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases... Agent:

20120295959 - Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of RNAse H1, in particular, by targeting natural antisense polynucleotides of RNAse H1. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression... Agent: Curna, Inc.

20120295953 - Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Protein 63 (p63), in particular, by targeting natural antisense polynucleotides of Tumor Protein 63 (p63). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders... Agent:

20120295963 - Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial: The present invention provides agents which are capable of regulating the function of a micro-RNA component which can be used to regulate an AChE-associated biological pathway. In addition, the present invention provides methods and pharmaceutical compositions for the treatment of various pathologies related to AChE-associated biological pathways such as apoptosis,... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

20120295961 - Modulation of hepatitis b virus (hbv) expression: Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.... Agent:

20120295964 - Retrograde transport viral vector system having envelope comprising fused glycoprotein: Provided is a lentiviral vector system which sustains a high-frequency retrograde transportation ability in animal brain and has a higher titer. A kit for preparing a retrograde transport viral vector, which comprises: (1) a packaging plasmid containing the gag gene and pol gene of HIV-1; (2) a packaging plasmid containing... Agent: Japan Science And Technology Agency

20120295962 - Targeting micrornas for the treatment of liver cancer: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide,... Agent: Regulus Therapeutics Inc.

20120295960 - Treatment regimen for parkinson's disease: Provided is an improved treatment for Parkinson's Disease where the efficacy of L-Dopa treatment is increased by including gene therapy in the treatment regimen. The combination therapy results in long-term improvements in response to L-Dopa and diminished side effects caused by L-Dopa.... Agent: Oxford Biomedica (uk) Ltd.

20120295863 - Dual-action compounds targeting adenosine a2a receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases: The present invention provides therapeutic agents for preventing and treating neurodegenerative diseases. These agents synergistically target both the adenosine A2A receptor (A2AR) and the equilibrative nucleoside transporter 1 (ENT1).... Agent:

20120295862 - Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting of nucleic acids: Embodiments are disclosed herein that involve C5-functionalized nucleic acids, which can be used for detecting a target in a nucleic acid. Particular embodiments disclose methods for making these compounds, wherein the compounds can be formed by coupling of an intermediate with a linker. Certain embodiments disclose the use of these... Agent: The Univeristy Of Idaho

20120295864 - Method for treating acute myeloid leukemia: The present invention relates to the use of BI 6727 or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) comprising the administration of a high dose of BI 6727 according to a specific dosage schedule, optionally in combination with cytarabine.... Agent: Boehringer Ingelheim International Gmbh

20120295865 - Shark-like chondroitin sulphate and process for the preparation thereof: The present invention provides a shark-like chondroitin sulphate and a process for the preparation thereof. In particular, the present invention relates to a shark-like chondroitin sulphate, having a very low amount of 4-sulphate, a high charge density and a biological activity comparable to natural chondroitin sulphates. The invention also relates... Agent: Gnosis S.p.a.

20120295866 - Synthesis and use of glycoside pro-drug analogs: The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug analogs. This invention relates to a method for the production of a broad group of glycosylated drugs, including but not limited to propofol, acetaminophen, and camptothecin carbohydrate derivatives.... Agent: Nutek Pharma Ltd.

20120295870 - Cross-linking of low-molecular weight and hih-molecular weight polysaccharides, preparation of injectable monphase hydrogels, polysaccharides and hydrogels obtained: A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing... Agent: Allergan, Inc.

20120295868 - Medical uses of glucans: The invention relates to a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto for use in the treatment of asthma and related diseases of abnormal pulmonary function in an animal. Also described is a method of treating asthma and related diseases of abnormal pulmonary function in... Agent: Biotec Pharmacon Asa

20120295867 - Method and pharmaceutical to treat spinal discs: Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a solution is injected into the disc. The solution includes chondroitin sulphate, glucosamine HCl, and dextrose. The solution may optionally include dimethyl sulfoxide and/or an anesthetic such as bupivicaine.... Agent:

20120295869 - Sterile hyaluronic acid solutions: Sterilized aqueous solution comprising 0.04% to 0.8% by weight hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and one or more buffer components selected from the group consisting of boric acid, sodium borate and sodium dihydrogen phosphate. The aqueous solution also has an ionic... Agent:

20120295871 - Heparin-based compositions and methods for the inhibition of metastasis: The invention provides the use in combination of a heparin containing composition that has anticoagulant activity when used alone, such as an unfractionated heparin or low molecular weight heparin, in combination with an inhibitor of the anticoagulation activity/effect or effect of heparin, for the inhibition of metastasis.... Agent:

20120295872 - Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma.... Agent: Universite De Liege

20120295873 - Branched soluble glucose polymers for peritoneal dialysis: The invention relates to branched soluble glucose polymers made of starch having an amylose content of at least 30 wt %, preferably 35 wt % to 80 wt %, having a glycosidic linkage α-1,6 content of 7% to 10%, preferably 8% to 9%, and a MW of 50,000 to 150,000... Agent: Roquette Freres

20120295875 - Boron-containing small molecules as antiprotozoal agents: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.... Agent: Anacor Pharmaceuticals, Inc.

20120295874 - Coferons and methods of making and using them: The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular... Agent: Purdue Research Foundation

20120295876 - Pyridazine derivatives, processes for their preparation and their use as fungicides: The present invention relates to novel pyridazine derivatives of formula (I) wherein R1 is methyl or ethyl; R2 is H or chloro; R3 is fluoro or chloro; R4 is fluoro or methoxy; and R5 is chloro or methoxy or an agrochemically usable salt from thereof, as active ingredients which have... Agent: Syngenta Crop Protection LLC

20120295877 - Therapeutic compounds: e

20120295878 - Method for the treatment of cancer: Provided is a method for determining the prognosis of cancer in a female patient with a solid tumor. The percentage of solid tumor cells expressing TUBB3 protein and the percentage of solid tumor cells expressing TUBB6 protein in a solid tumor sample from the patient is determined. Detection of TUBB6... Agent:

20120295879 - Nk1 antagonists: o

20120295880 - Compounds with modifying activity enhanced under hypoxic conditions: Compositions and methods for modifying one or more biologic targets are provided. Suitable targets include cells, DNA, proteins, enzymes, and/or a subject in need thereof. The compositions may exist as a monomer or multimer and are active in a biologic environment with enhanced activity in hypoxic environments and, thus, exhibit... Agent: Board Of Regents, The University Of Texas System

20120295882 - Tricyclic derivatives and their pharmaceutical use and compositions: m

20120295884 - Complement pathway modulators and uses thereof:

20120295883 - Compounds: The present invention relates to substituted pyrazolopyridine compounds, and pharmaceutically acceptable salts or esters thereof. The present invention further relates to therapeutic uses of pharmaceutical compositions comprising the substituted pyrazolopyridine compounds, for example, in cancer and neurodegenerative diseases.... Agent: Medical Research Council Technology

20120295881 - Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy: e

20120295885 - Inhibitors of bruton's tyrosine kinase: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as... Agent:

20120295886 - Antiviral compounds and their methods of use: e

20120295887 - Pharmaceutically acceptable salts of pyrrolo-nitrogenous heterocyclic derivatives, preparation method and medical use thereof: Pharmaceutically acceptable salts of pyrrolo-nitrogenous heterocyclic derivatives, preparation method and medical use thereof are disclosed. More specifically, pharmaceutically acceptable salts of (R,Z)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-methylene)-5-(2-hydroxy-3-morpholinyl-4-yl-propyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo[3,2-c]azepin-4-one presented by formula (I), the preparation method and the use thereof as therapeutic agents, especially as protein kinase inhibitors, are disclosed.... Agent: Jiangsu Hengrui Medicine Co., Ltd.

20120295888 - Use of an adrenal hormone-modifying agent: wherein n is 1 or 3; R is hydrogen or —C(O)N(Ra)(Rb) wherein Ra and Rb are independently —(C1-C4)alkyl, or —(C1-C4)alkyl-(C5-C7)aryl, wherein each of Ra and Rb is optionally substituted by —(C1-C4)alkoxy; R1, R2, and R3, are independently hydrogen, halogen, cyano or —(C6-C10) aryl, wherein said —(C6-C10)aryl is optionally substituted by... Agent:

20120295889 - 3-arylamino pyridine derivatives: pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such... Agent: Merck Serono S.a.

20120295890 - Glycosaminoglycan inhibitors: Provided herein are chondroitin sulfate inhibitors, including modulators of glycosylation, and/or sulfation of galactose or N-acetyl galactosamine glycosaminoglycans.... Agent: Zacharon Pharmaceutical, Inc.

20120295891 - Novel substituted triazole derivatives as gamma secretase modulators: wherein Het1, R1, R2, A1, A2, A3, A4, L1, and L2 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active... Agent:

20120295893 - Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs: The present invention provides pharmaceutical compositions comprising a flumazenil, and methods of alleviating or counteracting residual effects (e.g. drowsiness) associated with the administration of sleep/hypnotic drugs or alleviating effects of alcohol intoxication, using self administration modes of delivery.... Agent: Coeruleus Ltd.

20120295892 - Gabaergic receptor subtype selective ligands and their uses: Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor... Agent: Uwm Research Foundation, Inc.

20120295894 - Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof: Described herein are novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.... Agent:

20120295895 - Compounds and methods of treating ocular disorders: s

20120295896 - Oxadiazole inhibitors of leukotriene production: and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.... Agent: Boehringer Ingelheim International Gmbh

20120295897 - Spiro-oxindole compounds and their uses as therapeutic agents: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.... Agent: Xenon Pharmaceuticals Inc.

20120295898 - Antiviral therapy: The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent:

20120295899 - Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, n, W, X, R1 and R6, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of... Agent: Bristol-myers Squibb Company

20120295900 - 1,3-oxazines as bace 1 and/or bace2 inhibitors:

20120295902 - Hetaryl-[1,8]naphthyridine derivatives:

20120295901 - Novel substituted bicyclic triazole derivatives as gamma secretase modulators: wherein Het1, R1, R2, A1, A2, A3, A4, L1, and L2 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active... Agent:

20120295903 - Flavin derivatives: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.... Agent:

20120295904 - Hematopoietic growth factor mimetic small molecule compounds and their uses: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.... Agent: Ligand Pharmaceuticals Inc.

20120295905 - New anti-malarial agents: The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.... Agent: Mmv Medicines For Malaria Venture

20120295906 - Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene-and furane-derivatives as kinase inhibitors: The present invention provides compounds of the formula (I), or the pharmaceutically acceptable salts thereof, wherein G, W, R2, R3, R4, R5 and R6 are as defined in the specification. Further objects of the invention are processes and intermediates for the preparation of the compounds of the formula (I), pharmaceutical... Agent: Nerviano Medical Sciences S.r.l.

20120295907 - Insecticidal compounds: The present invention relates to bis-amide derivatives of formula (I), to processes and intermediates for preparing them, to methods of using them to control insect, acarine, nematode and mollusc pests, and to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them.... Agent: Syngenta Crop Protection, LLC

20120295908 - Pyrimidinyl pyridazinone derivatives: Compounds selected from the group according to claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120295909 - Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application: m

20120295910 - New phenylsulfamoyl benzamide derivatives as bradykinin antagonists: The present invention relates to new sulfonamide derivatives of formula (I), wherein R1-R8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these same compounds, pharmacological compositions containing... Agent:

20120295911 - Novel compounds and compositions for treatment of breathing control disorders or diseases: The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically... Agent: Galleon Pharmaceuticals, Inc.

20120295912 - Piperazinylpiperidine derivatives as chemokine receptor antagonists: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as... Agent: Incyte Corporation

20120295913 - Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors: In one aspect, the invention relates to bicyclic pyrazole compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated... Agent:

20120295914 - Combination of adrenergic receptor agonist alpha-1 or alpha-2, preferably brimonidine with fillers, preferably hyaluronic acid: A combination of a quantity of adrenergic receptor agonist α-1 or α-2, and preferably product known as brimonidine, with fillers, and preferably with hyaluronic acid, for decreasing skin or cutaneous reactions is described.... Agent: Galderma Research & Development

20120295915 - Azabenzimidazoles as fatty acid synthase inhibitors: c

20120295916 - Orodispersible tablet containing compacted sildenafil base: The invention relates to a process for the preparation of a pharmaceutical intermediate, comprising the steps of (i) mixing (a-i) sildenafil base, (b-i) wicking agent, (c-i) disintegrant, (d-i) optionally glidant; (ii) compacting the mixture; and (iii) milling the compacted material; and to an intermediate obtainable by that process. In addition,... Agent: Ratiopharm Gmbh

20120295917 - Imatinib dichloroacetate and anti-cancer agent comprising the same: The present invention relates to imatinib dichloroacetate and an anti-cancer agent comprising the same. The imatinib dichloroacetate of the present invention can inhibit tyrosine kinase as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction, and show significantly... Agent: Celltrion Chemical Research Institute

20120295919 - Arylpiperazine opioid receptor antagonists: Provided are opioid receptor antagonists represented by the formula (I) where R, Y3, R1, R2, R3, R4 and R5 are as defined herein.... Agent: Research Triangle Institute

20120295918 - Cancer treatment method: Invented is a method of treating cancer or a pre-cancerous syndrome in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a non-peptide thrombopoietin (TPO) receptor agonist to such mammal, suitably a human.... Agent: Glaxosmithkline, LLC.

20120295920 - 5-amino-4-hydroxypentoyl amides: n is 0 or 1; A is CH or N; R5 and R6 are hydrogen, C1-4alkyl, halo; R7 and R8 are C1-4alkyl or C1-4alkoxyC1-4alkyl; R9 is C1-4alkyl, cyclopropyl, trifluoromethyl, C1-4alkoxy, or dimethylamino; R10 is hydrogen, C1-4alkyl, cyclopropyl, trifluoromethyl, C1-4alkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions... Agent:

20120295921 - Pyridyl piperidine orexin receptor antagonists: The present invention is directed to pyridyl piperidine compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent:

20120295923 - Aminocyclohexanes and aminotetrahydropyrans and related compounds as gamma-secretase modulators: e

20120295922 - Compounds for use in treatment of mucositis: The present invention provides methods for treating and/or preventing mucostitis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.... Agent: Polymedix, Inc.

20120295924 - Thienopyrimidinedione derivatives as trpa1 modulators: The present invention is related to novel thienopyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds... Agent: Glenmark Pharmaceuticals S.a.

20120295927 - Methods of using selective chemotherapeutic agents for targeting tumor cells: A method for treating cancer tumors, particularly ovarian cancer tumors, is described, where fused cyclic pyrimidine having a cancer treating ability is selectively delivered to an FR expressing cancerous tumor.... Agent: Duquesne University Of The Holy Ghost

20120295926 - Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same: m

20120295925 - Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds: This invention relates to novel compounds of the Formula A, B, or C, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier.... Agent: Concert Pharmaceuticals, Inc.

20120295928 - Methods for detecting and reducing impurities of lapatinib and salts thereof: i

20120295929 - Compositions and methods for treating and preventing dermatoses: The invention encompasses protectant agents including uracil or a metabolite thereof that effectively prevent and/or treat the cutaneous toxicities and dermatological side-effects associated with chemotherapeutic agents. Additionally, and surprisingly compositions including uracil or a metabolite thereof are effective for treating or preventing various dermatoses.... Agent:

20120295930 - Novel process for the preparation of cis-nucleoside derivative: The present invention relates to an improved process for the preparation of cis-nucleoside derivative of formula-1 involving chlorination of the compound of formula-2 followed by reaction with compound of formula-3 in presence of a base to get compound of formula-4, reacting the compound of formula-4 with an alkyl halide (RiX)... Agent:

20120295931 - Spiroindoline compounds for use as anthelminthics: This invention relates to spiroindoline compounds for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments.... Agent:

20120295932 - Method for the treatment of cancer: (b) at least one chemotherapeutic agent other than an antiandrogen or an inhibitor of androgen synthesis for the treatment of cancer characterized by a solid tumor, other than prostate cancer, in a male patient. The antiandrogen, the inhibitor of androgen synthesis, or the combination of both may be administered before,... Agent: Western Connecticut Health Network, Inc.

20120295933 - Treatment of copd, gastro-esophageal reflux disease (gerd), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibators, lra drugs, anti-h1 and/or: The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.... Agent:

20120295934 - New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds: wherein R1, R2, A, E, G and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) and may be used for the treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, obesity, cardiovascular diseases, myocardial... Agent:

20120295935 - Mixed aminal pharmaceutical compositions and uses thereof: Described herein are pharmaceutical compositions for the administration of one or more mixed aminals, as defined herein, including salubrinal and analogs and derivatives of salubrinal, and methods for treating diseases or disorders arising from apoptosis, particularly for treating diseases or disorders arising from integrated stress response-induced apoptosis, such as occurs... Agent:

20120295936 - Compositions and methods for treating seizure disorders: Disclosed are methods of treating a seizure disorder by administering to a patient in need of such treatment a compound having the following formula:... Agent: Allergan, Inc.

20120295937 - Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc): The invention provides therapeutic methods that include administering a stable nitroxide to a subject that has, is suspected to have, or is at risk for having a condition associated with reduced VHL or elevated HIF-2α.... Agent: Usdhhs Office Of Technology, Nih

20120295938 - Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial... Agent:

20120295939 - Anti-viral agent: A method of suppressing the proliferation of virus comprises administering an antiviral agent comprising as an effective component at least one member selected from the group consisting of 5,7,4′-trihydroxy-3′,5′-dimethoxyflavone, 3-hydroxypyridine, p-hydroxybenzaldehyde and vanillin to one in need of suppressing of viral proliferation.... Agent:

20120295940 - Compositions for treating mastitis: The present disclosure relates to compositions that are effective in controlling or in preventing mastitis in an domesticated animal. The disclosed compositions comprise a biocidal system, comprising a primary biocide and a pH buffer component; a skin conditioner and moisturizer; a cationic or ionic surfactant having an HLB of from... Agent: Noble Ion, LLC

20120295941 - method for producing intermediates for the production of macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof: The present invention relates to an improved method for the synthesis of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof.... Agent:

20120295942 - Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists: There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.... Agent:

20120295943 - Cycloalkylamine derivatives: [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R1a and R1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R2a and R2b are the same or different... Agent:

20120295944 - Treatment of hyperproliferative disorders with diarylhydantoin compounds: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.... Agent: The Regents Of The University Of California

20120295945 - Buccal, polar and non-polar spray containing ondansetron: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II:... Agent:

20120295946 - Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof: The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production... Agent: Raptor Pharmaceutical Corp.

20120295947 - Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof: The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory... Agent: Arena Pharmaceuticals, Inc.

20120295948 - Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors: The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human... Agent: Anygen Co., Ltd.

20120295965 - Fused thiophenes as dual inhibitors of egfr/vegfr and their use in the treatment of cancer: Disclosed are compositions and methods related to identification of modulators of EGFR and VEGFR.... Agent:

20120295966 - Chromone inhibitors of s-nitrosoglutathione reductase: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.... Agent: N30 Pharmaceuticals, LLC

20120295967 - High concentration olopatadine ophthalmic composition: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase... Agent:

20120295968 - Pharmaceutical composition comprising cannabinoids: The present invention relates to a pharmaceutical composition comprising Δ9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resvertrol, and combinations thereof, wherein the composition exhibits an increased but negated psychoactivity with concurrent enhancement... Agent: Brooks Kelly Research, LLC

20120295969 - Novel muscle relaxant using negatively charged gold with choline: In order to achieve muscle relaxing effect and anti-atrial fibrillation effect, the present invention provides gold nanoparticles complexes. Gold nanoparticles complexes include negatively charged gold nanoparticles bound to choline or spermidine through ionic bonds according to the purpose to be achieved, which form gold nanoparticles-choline complexes or gold nanoparticles-spermidine complexes.... Agent:

20120295970 - Therapeutic compositions: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.... Agent: Leo Laboratories Limited

20120295971 - Therapeutic compositions: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.... Agent: Leo Laboratories Limited

20120295972 - Ester derivatives of bimatoprost compositions and methods: Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.... Agent:

20120295973 - Methods and compositions of derivatives of probucol for the treatment of diabetes: This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a monoester of probucol, particularly the monosuccinic acid ester, or a pharmaceutically acceptable salt or derivative thereof.... Agent: Salutria Pharmaceuticals LLC

20120295976 - Composition and/or method for preventing recurrence of stroke: By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the... Agent:

20120295975 - Methods of treating inflammatory conditions: The present invention provides methods of treating a β-arrestin2 mediated and/or GPR120 mediated response in a subject. The β-arrestin2 mediated and/or GPR120 mediated response can be inflammation, including diabetes, inflammation associated with obesity and obesity. The methods can comprise administering to a subject a therapeutically effective amount of a compound... Agent: The Regents Of The University Of California

20120295974 - Trans-, trans-conjugated linoleic acid compositions and use thereof: This invention relates generally to trans-,trans-conjugated linoleic acid compositions and use thereof, and in particular to trans-,trans-conjugated linoleic acid produced from photoisomerization of soy oil in the presence of an antioxidant, and used in pharmaceutical, nutraceutical and human and animal food compositions for improved health. The invention also relates generally... Agent: Board Of Trustees Of The University Of Arkansas

20120295977 - Organosulfur prodrugs for the prevention and treatment of infectious diseases: A method for enhancing the overall beneficial immune system response in a host that works in conjunction with the host's natural immune system response to enhance the host's ability to eliminate infectious microbes while simultaneously suppressing the toxicity of the immune system response to the host. Allium related organosulfur compounds... Agent:

20120295978 - Diclofenac gel: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.... Agent: Nuvo Research Inc.

20120295980 - Compounds and methods for delivery of prostacyclin analogs: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and... Agent: United Therapeutics Corporation

20120295979 - Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress: Compositions and methods described herein are based on the use of the drug sulindac, a non steroidal anti-inflammatory drug (NSAID), for protecting retinal pigment epithelial cells against oxidative stress which is a major component of macular degeneration. Described herein is a new use for sulindac.... Agent: Florida Atlantic University

20120295981 - Tetrasubstituted benzenes: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.... Agent: Envivo Pharmaceuticals, Inc.

20120295982 - Treating human male copd patients with oral bedoradrine: A method of treating a human male patient is disclosed. Enterally administering bedoradrine or a pharmaceutically acceptable salt thereof to a human male patient who is suffering from a medical condition that is responsive to bedoradrine or a pharmaceutically acceptable salt thereof, is useful and benefits human males versus human... Agent: Medicinova, Inc.

20120295983 - Stabilized cationic ammonium compounds for topical compositions: Stabilized cationic ammonium compounds are described. The compounds are stabilized with metal chelators that impede the generation of nitrogen comprising groups from the cationic ammonium compounds.... Agent: Conopco, Inc., D/b/a Unilever

20120295984 - Antibacterial cosmetic applicator: Antibacterial cosmetic brush hairs include synthetic fibers treated with quaternary ammonium salt, phenolic compound, and acid. The antibacterial cosmetic brush hairs inhibit the loss of the antibacterial effect through washing or the like.... Agent:

20120295985 - Methods for improving blood glucose control: The present invention is concerned with a method for improving blood glucose control or for preventing or treating a condition requiring increasing insulin sensitivity or reducing insulin resistance in a subject in need of such control which comprises administering to the subject a composition comprising a therapeutically effective amount of... Agent:

20120295986 - Calcium sequestering composition: This invention relates to compositions which are capable of sequestering calcium ions and are derived in part from renewable carbohydrate feedstocks. The calcium sequestering compositions are mixtures containing one or more hydroxycarboxylic acid salts and one or more aluminum salts.... Agent:

20120295987 - Cleansing bar: A cleansing bar comprising at least one member chosen from clay and talc, wherein a total amount of clay and talc is present in an amount that is greater than any other material in the cleansing bar, at least one cleanser chosen from soap and surfactant, and a binder present... Agent: Colgate-palmolive Company

20120295988 - Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers: A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use... Agent:

20120295989 - Oil-based composition: A method for producing a gel-like oily composition including the following components (A), (B), and (C): (A) 4 to 60% by weight of a sphingosine represented by the formula (1) (wherein R1 represents a hydrocarbon group having 4 to 30 carbon atoms; Y represents a methylene group, a methine group,... Agent: Kao Corporation

20120295990 - Insulin receptor substrate 1 (irs1) protein srm/mrm assay: The current disclosure provides for specific peptides from the Insulin Receptor Substrate 1 (IRS1) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying IRS1 directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include:... Agent: Expression Pathology, Inc

  
11/15/2012 > 163 patent applications in 125 patent subcategories. recently filed with US Patent Office

20120289452 - Compositions and methods for treating and preventing necrosis: A method for treating and/or preventing cell necrosis and diseases associated therewith, comprising the inhibition of one or more elastase enzymes within said cells.... Agent: Ilana Nathan

20120289453 - Novel glp-1 compounds: Novel GLP-1 compounds and their therapeutic use.... Agent: Novo Nordisk A/s

20120289454 - Metallodrugs having improved pharmacological properties, and methods of manufacture and use thereof: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a... Agent: Metallopharm LLC

20120289455 - Monocarbams:

20120289456 - Antimicrobial protein compositions and uses thereof: Several bacterial species were isolated from marine segment obtained from seabed sediment at depths exceeding 1700 feet. At least four of the bacteria produced a compound that showed antibacterial activity against one or more multiple-drug-resistant (MDR) bacteria isolated from hospitals and clinics. One isolate, SJCH-12, exhibited a broad range of... Agent: St. Joseph's Children's Hospital

20120289457 - Peptide oligonucleotide conjugates: Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.... Agent: Avi Biopharma, Inc.

20120289458 - Treatment of influenza virus infection: The present invention provides method for the treatment of an ongoing influenza infection by administering a polypeptide to a subject suffering from an influenza infection. The polypeptide consists of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or an 8 to 40 amino acid residue portion thereof.... Agent: The Administrators Of The Tulane Educational Fund

20120289459 - Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8: New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections... Agent: Alternative Gene Expression, S.l.

20120289460 - Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases: This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or... Agent: Synergy Pharmaceuticals Inc.

20120289461 - Protein synthesis promoter: A protein synthesis promoter that exhibits a protein synthesis-promoting effect includes a whey protein hydrolyzate having a molecular weight distribution that is within a range of 10 kDa or less and has a main peak of 200 Da to 3 kDa, an average peptide length (APL) of 2 to 8,... Agent: Megmilk Snow Brand Co., Ltd.

20120289462 - Insulin preparation: The present invention relates to an insulin preparation that contains a self-assembling peptide. More specifically, the present invention is an insulin preparation containing a self-assembling peptide of SEQ ID NO: 1.... Agent:

20120289463 - Compositions and methods for promoting epithelialization and wound closure: Compositions for antagonizing phosphorylation and subsequent degradation of glycogen synthase kinase 3 beta (GSK3β) in epidermal cells are disclosed. GSK3β phosphorylation antagonists include molecules that function to inhibit or reduce the binding activity or enzymatic activity of an upstream signaling molecule leading to GSK3β phosphorylation, or by downregulating the expression... Agent: New York University

20120289464 - Angiogenically effective unit dose of fgf-2 and method of use: The present invention provides a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering... Agent: Novartis Vaccines And Diagnostics, Inc.

20120289465 - Use of inhalable powder formulation comprising growth hormone for preventing or treating nmda receptor hypofunction-related diseases: A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in... Agent: Gcbio Corp.

20120289466 - Glucagon-like-peptide-2 (glp-2) analogues: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16,... Agent: Zealand Pharma A/s

20120289467 - Compositions and methods utilizing fibrin beta chain fragments: A composition including a peptide sequence of the formula βX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide... Agent: University Of Maryland, Baltimore

20120289468 - Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto: The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.... Agent: Grifols Therapeutics Inc.

20120289469 - Methods and compositions for maintaining active agents in intra-articular spaces: Methods and compositions for maintaining an active agent in an intra-articular space are disclosed. Methods of delivering the compositions to an intra-articular space and methods of making the compositions also are disclosed. The compositions comprise an active agent and a polymer comprising at least one cationic group. A fluid including... Agent: Bend Research, Inc.

20120289471 - Novel compounds with high therapeutic index: The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced... Agent: Signature R&d Holdings, LLC

20120289470 - Transmucosal administration of drug compositions for treating and preventing disorders in animals: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable... Agent: Velcera Pharmaceuticals, Inc

20120289472 - Molecules capable of inducing cell death by targeting the mitochondria and applications thereof: The invention relates to the use of derivatives of the membrane insertion regions of proteins of the Bcl-2 family to induce cell death by targeting the mitochondria, characterised in that said derivatives are peptides belonging to regions α5 and/or α6 of the Bax protein or equivalent regions found in the... Agent:

20120289474 - 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c] isoquinoline derivatives: e

20120289473 - Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water-soluble extract from plant of solanum genus: The present invention relates to a pharmaceutical composition for preventing and treating inflammation and cutaneous photodamage, which contains a water-soluble extract from a plant of Solanum genus. The composition also has a photoprotective effect, and can be used as a cosmetic composition.... Agent: G & E Herbal Biotechnology Co., Ltd.

20120289580 - Antisense modulation of ptp1b expression: Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.... Agent:

20120289581 - Diagnostic, prognostic and therapeutic uses of long non-coding rnas for cancer and regenerative medicine: Long non-coding RNAs (lncRNAs) and methods of using them diagnostically and therapeutically for treatment of cancer, stem cell therapy, or regenerative medicine are disclosed. In particular, the invention relates to lncRNAs that that play roles in regulation of genes involved in cell proliferation, differentiation, and apoptosis. Such lncRNAs can be... Agent:

20120289579 - Impaired wound healing compositions and treatments: Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.... Agent:

20120289582 - Methods for diagnosing and treating a pathology associated with a synonymous mutation occuring within a gene of interest: The present invention relates to a method for diagnosing and/or prognosing a pathology (such as inflammatory dis-ease, especially Crohn disease) associated with a synonymous mutation occurring within a gene of interest (such as IRGM, NOD2 or BSN) in a subject and to a method for treating such pathology in a... Agent:

20120289583 - Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3): The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Insulin Receptor Substrate 2 (IRS2) polynucleotides, in particular, by targeting natural antisense polynucleotides of Insulin Receptor Substrate 2 (IRS2) polynucleotides and Transcription factor E3 (TFE3). The invention also relates to the identification of these antisense... Agent: Curna, Inc.

20120289578 - Use of rna interference for treating or reducing pain: A use of a nucleic acid molecule mediating RNA interference for treating or reducing pain is disclosed. The nucleic acid molecule has a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, and is used for effectively inhibiting expression... Agent: Fu-jen Catholic University

20120289584 - Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules: This disclosure provides compositions that are useful combined with therapeutics, and in the diagnosis and treatment of diseases and conditions. The compositions are useful for delivery of agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.... Agent: Agave Pharma, Incorporated

20120289585 - Sdf-1 delivery for treating ischemic tissue: A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left... Agent:

20120289586 - Sdf-1 delivery for treating ischemic tissue: A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left... Agent:

20120289475 - Certain compounds, compositions and methods: The present invention provides certain tetrahydrouridine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of making and using such compounds.... Agent:

20120289476 - Methods for treating methylmalonic acidemia: Methods for treating methylmalonic acidemia in which at least one allele of a gene associated with MMA (e.g., the MUT, MMAA, or MMAB gene) contains a mutation (e.g., nonsense mutation) that results in a premature stop codon in RNA encoded by an allele of the gene associated with MMA involving... Agent:

20120289477 - Biotechnological sulphated chondroitin sulphate at position 4 or 6 on the same polysaccharide chain, and process for the preparation thereof: A process for the preparation of a chondroitin sulphate salt with an average molecular weight (Mw) of 10-30 kDa via chemical sulphation of an unsulphated chondroitin backbone is provided. The unsulphated chondroitin can be obtained by acid hydrolysis of a capsular polysaccharide K4 made directly from E. coli strain O5:K4:H4... Agent:

20120289478 - Hyaluronic acid esters, their preparation and use in dermatology: New ester derivatives of hyaluronic acid with hydroxy-cinnamic acid, their rheological and anti-radical properties are used as protective agents in dermatology.... Agent: Rottapharm S.p.a.

20120289480 - Cyclodextrin-based polymers for therapeutics delivery: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from... Agent: Cerulean Pharma Inc.

20120289479 - Materials and methods related to sodium/potassium adenosine triphosphate and cholesterol: This invention is based in part on the elucidation of new structural conformations and functions of the sodium/potassium adenosine triphosphate synthase (Na/K ATPase), and especially elucidation of new binding sites and interactions. The present invention provides practical applications of several surprising structural and functional relationships between Na/K ATPase and compounds... Agent: University Of Toledo

20120289481 - Compositions and methods for treating cancer: The instant invention provides a method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mTOR inhibitor and an αvβ3 integrin antagonist, wherein the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus or a combination thereof.... Agent:

20120289482 - Method for modulating or controlling connexin 43(cx43) level of a cell and reducing arrhythmic risk: A method of modulating or controlling connexin 43 (Cx43) level of a cell includes inducing mitochondrial reactive oxygen species (ROS) production in the cell.... Agent: U.s. Department Of Veterans Affairs

20120289483 - Compounds for the treatment of proliferative disorders: m

20120289484 - Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same: Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC. One embodiment described herein relates to the transdermal administration of a Δ9-THC prodrug for treating and preventing diseases and/or disorders.... Agent: Alltranz Inc.

20120289485 - Metformin salts of salicylic acid and its congeners: intermediates used in the preparation of such compounds, processes for the preparation of such compounds of the formula VI and formula VII and such intermediates, pharmaceutical compositions comprising such compounds of the formula VI and such compounds of the formula VII, and the uses of such compounds of the formula... Agent:

20120289487 - Pharmaceutical use of multicyclic compounds as anti-aids agents: This invention refers to pharmaceutical use of multicyclic compounds chosen from ingenols, lanosta-8,24-dien-3-ols and their mixtures, as anti-AIDS agents.... Agent: Amaz&#xd4 Nia Fitomedicamentos Ltda

20120289486 - Treatment of eyelid dermatitis: A method for the treatment of eyelid dermatitis and/or dermatitis of the periorbital area is provided.... Agent:

20120289489 - Non-sedating antihistamine injection formulations and methods of use thereof: Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In... Agent: Jdp Therapeutics, Inc.

20120289488 - Steroid-sparing effects of beta-adrenergic inverse agonists and uses thereof: Provided herein is a pharmaceutical composition combination which comprises (a) a corticosteroid and (b) b-adrenergic receptor antagonist characterised in that active ingredients (a) and (b) form part of a single composition. Further provided is a method of treating a human or animal patient suffering from or susceptible to a respiratory... Agent:

20120289490 - Compositions and methods for enhancing corticosteroid delivery: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and... Agent: Medicis Pharmaceutical Corporation

20120289491 - Methods for the treatment of a central nervous system injury via a tapered administration protocol: The present invention provides methods for the treatment or the prevention of neuronal damage in the CNS. Specifically, the methods of the invention provide for the administration of a therapeutically effective amount of a progestin or progestin metabolite following a traumatic or ischemic injury to the CNS such that, prior... Agent: Emory University

20120289492 - Methods of treating mitochondrial disorders using metalloporphyrins: Methods of treating a mitochondrial disorder including epilepsy, a neurological disorder, an inherited mitochondrial disease or inherited epilepsies, a pediatric epilepsy, an encephalopathy or a pediatric movement disorder are provided, as well as compounds useful in the methods of the invention, such as metalloporphyrin compounds as disclosed herein.... Agent: The Regents Of The University Of Colorado, A Body Corporate

20120289495 - Compounds and methods: t

20120289493 - Fused heterocyclic compounds as ion channel modulators:

20120289494 - Spiro-oxindole mdm2 antagonists: Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.... Agent: The Regents Of The University Of Michigan

20120289497 - Fused pyridine derivatives: Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R1, R2, R3, Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the... Agent: Xuanzhu Pharma Co., Ltd.

20120289496 - Novel compounds as modulators of protein kinases: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.... Agent: Rhizen Pharmaceuticals Sa

20120289498 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine compounds, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation... Agent: The Regents Of The University Of Michigan

20120289499 - Process: Substantially pure methylthioninium chloride pentahydrate form A is prepared from methylthioninium chloride by phase equilibration of suspensions, crystallization or solvent evaporation, whereby the water content of the solvent corresponds to a water activity of at least 0.4 at 25° C., and controlled drying of said methylthioninium chloride pentahydrate form A... Agent: Wista Laboratories Ltd.

20120289500 - Potassium channel modulators: b

20120289501 - Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls: The invention relates to new derivatives of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a proliferative disease.... Agent: Novartis Ag

20120289502 - Imidazole derivatives: e

20120289503 - Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease: A liquid composition that is an aqueous solution of a compound of formula (I), wherein the aqueous solution has a pH from about 3.0 to about 5.0. The liquid composition may be used in the treatment of a disorder selected from hyperproliferative diseases, autoimmune diseases and heart diseases.... Agent: Aprea Ab

20120289504 - Benzoimidazole compounds and uses thereof: This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in... Agent: Astrazeneca Ab

20120289505 - Inhibitors of diacylglycerol acyl transferase: The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their... Agent:

20120289506 - 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same: 5-membered heterocyclic derivatives represented by general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring... Agent: Kissei Pharmaceutical Co., Ltd.

20120289507 - Organic compounds as smo inhibitors: The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their... Agent: Novartis Ag

20120289508 - Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof: The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers... Agent:

20120289509 - Heterocyclic compound as protein kinase inhibitor: Provided are novel heterocyclic compounds useful as anti-cancer drugs by suppressing protein kinase activities of growth factor receptors such as c-Met, pharmaceutical compositions containing the same, and methods for using the compound.... Agent: Neopharm Co., Ltd.

20120289510 - Benzyl amines, a process for their production and their use as anti-inflammtory agents: o

20120289511 - Compositions and methods for treating alzheimer's disease: The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.... Agent: Eip Pharma, LLC

20120289512 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.... Agent: Abbott Laboratories

20120289513 - (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives: e

20120289514 - Pharmaceutical composition for treating alcohol dependency:

20120289515 - Combination therapy for cognitive distortions, resisting relapse of unipolar non-psychotic depression: The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such... Agent:

20120289516 - Methods for administering aripiprazole: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests... Agent: Alkermes, Inc.

20120289517 - Solid pharmaceutical composition for oral administration: 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide (compound a) or an acid addition salt thereof, and (B) organic acid selected from the group consisting of tartaric acid, malic acid, ascorbic acid and benzoic acid. An improvement is achieved in the dissolubility of the compound a, which is useful as a therapeutic agent for hypercholesterolemia, arteriosclerosis, and... Agent: Kowa Co., Ltd.

20120289518 - Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same: [

20120289519 - Protease inhibitors:

20120289520 - Chemical compounds 785: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity... Agent: Astrazeneca Ab

20120289521 - Treatment of acne and other diseases: The invention relates to compounds for the treatment of dermatological diseases where inflammation, matrix metalloproteinases (MMPs) and peroxisome proliferator-activated receptors (PPARs) play a role in mediating the disease, such as the treatment of acne with Pemirolast or a closely related compound thereof.... Agent:

20120289522 - Compounds as lysophosphatidic acid receptor antagonists: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent: Amira Pharmaceuticals Inc.

20120289523 - Pyrrolo [3,2-e] [1,2,4] triazolo [1,5-a] pyrimidines derivatives as inhibitors of microglia activation: The invention relates to novel compounds useful in the treatment and prophylaxis of disease. Compounds of the formula (I) wherein X is halogen, independently selected form chlorine and fluorine and n is 0, 1 or 2, and their pharmaceutically acceptable salts are useful in the treatment and prophylaxis of diseases... Agent: Senexis Limited

20120289524 - Pyrrolo [3,2-e] [1,2,4] triazolo [1,5-a] pyrimidines derivatives as inhibitors of microglia activation: e

20120289525 - Pyrimidine ether derivatives and methods of use thereof: The present invention relates to Pyrimidine Ether Derivatives, compositions comprising a Pyrimidine Ether Derivative, and methods of using the Pyrimidine Ether Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR) in a patient.... Agent:

20120289526 - Imidazolidinedione derivatives: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and... Agent:

20120289528 - Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity: wherein the radicals as defined herein, or of a pharmaceutically acceptable salt thereof, for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the Bcr-Abl oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor 1), DDR2 (discoidin domain receptor 2)... Agent:

20120289527 - Mono-hydrochloric salts of an inhibitor of histone deacetylase: This invention provides novel crystalline forms of mono-HCl salts and a mono-HCl salt hydrate of JNJ-26481585, an inhibitor of histone deacetylases. The invention also relates to processes for production of these forms, to intermediates used in these processes, to pharmaceutical compositions comprising these forms, and to the use of these... Agent:

20120289529 - Combinations of trospium and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289530 - Combinations of trospium and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289531 - Combinations of trospium and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289532 - Method for the production of amorphous rifaximin: The present invention relates to a new amorphous form of rifaximin and to methods for the preparation thereof by means of high energy milling or Spray drying. The present invention further relates to a new amorphous form for use as medicament and to the pharmaceutical compositions composing it.... Agent:

20120289533 - Use of manzamine compounds in anti-cancer therapeutic regimens: Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion... Agent:

20120289534 - Package for improved treatment of conditions: The present invention provides an improved package from the administration of active ingredients. The present invention provides a package comprising: a standard portion comprising one or more active ingredients in a plurality of different potencies, and a rescue portion comprising one or more same or different active ingredients. The package... Agent: Kirax Corporation

20120289535 - Dual phase drug release system: e

20120289536 - Pharmaceutical compositions comprising colloidal silicon dioxide: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.... Agent:

20120289538 - Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are... Agent: Medicis Pharmaceutical Corporation

20120289537 - Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy: Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namelyl, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to... Agent: Medicis Pharmaceutical Corporation

20120289539 - Combinations of trospium and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289540 - Kinase inhibitors useful for the treatment of proliferative diseases: The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase... Agent: Deciphera Pharmaceuticals, LLC

20120289541 - Methods and compositions for applying moxifloxacin to the ear: Methods and materials useful for applying moxifloxacin to the ear are described. The methods involve delivering a composition that contains at least one viscogenic agent and moxifloxacin or a salt thereof to the epidermal surface of the tympanic membrane via the ear canal. The composition is delivered to the tympanic... Agent: Novartis Ag

20120289542 - Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and an oral antidiabetic agent for treating and/or... Agent: Gilead Sciences, Inc.

20120289543 - Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289544 - Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289545 - Maleate salts of (e)-n--4-(dimethylamino)-2-butenamide and crystalline forms thereof: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.... Agent:

20120289546 - Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine: e

20120289547 - Combinations of propiverine and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release propiverine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289548 - Oligomer-opioid agonist conjugates: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.... Agent: Nektar Therapeutics

20120289550 - Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same: The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate. Methods of using such compositions are also provided... Agent: The Curators Of The University Of Missouri

20120289549 - New hexahydropyrroloimidazolone compounds: wherein R1, R2, R3 and A are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful as inhibitors of hormone sensitive lipase (HSL) and may be used in the treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, obesity, cardiovascular diseases, myocardial dysfunction, inflammation,... Agent:

20120289551 - Mineralocorticoid receptor antagonists: Mineralocorticoid receptor antagonists, of which the following is exemplary.... Agent: Boehringer Ingelheim International Gmbh

20120289552 - Aryl ureas with angiogenesis inhibiting activity: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.... Agent: Bayer Healthcare LLC

20120289553 - Oral liquid pharmaceutical composition of nifedipine: It relates to an oral liquid pharmaceutical composition comprising: a) nifedipine in an amount comprised between 0.1% and 1% w/w; b) ethanol in an amount comprised between 38% and 58% w/w; c) water in an amount comprised between 4% and 12% w/w; d) glycerine in an amount comprised between 30%... Agent: Laboratorio Reig Jofre, S.a.

20120289554 - 4-dimethylaminobutyric acid derivatives: wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments in methods for the treatment of diseases modulated... Agent:

20120289555 - Novel s-nitrosoglutathione reductase inhibitors: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.... Agent: N30 Pharmaceuticals, LLC

20120289556 - Methods for treating conditions caused by higher-than-normal dopaminergic activity in basal ganglia: Treatment of humans suffering from conditions caused by higher-than-normal dopaminergic activity in basal ganglia includes administering the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts.... Agent: Neuropill, Inc.

20120289557 - Protein synthesis required for long-term memory is induced by pkc activation on days preceding associative learning: The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator... Agent: Blanchette Rockefeller Neurosciences Institute

20120289558 - Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor: In accordance with the present invention, it has been discovered that compounds which modulate the γ-secretase enzyme to make more of the shorter, less toxic and less aggregation-prone Aβ peptides (such as Aβ37 and Aβ38), while making less of the longer and more toxic and aggregation-prone AB peptides (such as... Agent: Neurogenetic Pharmaceuticals, Inc.

20120289559 - Method for producing fine powder and the fine powder produced by the same: Disclosed is a manufacturing method for a fine powder exhibiting improved solubility, little impurity contamination, and a high recovery rate. Material to be ground and a grinding medium are suspended and stirred in a liquefied inert gas dispersion medium such as dried ice, and the material to be ground is... Agent:

20120289562 - Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release darifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289567 - Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release darifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289561 - Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289566 - Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289563 - Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder: Disclosed are pharmaceutical compositions comprising a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder, the method comprising... Agent: Theravida, Inc.

20120289564 - Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289568 - Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289560 - Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289565 - Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20120289569 - Inhibitors of ubiquitin e1: The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.... Agent: The Usa, As Represented By The Secretary, Department Of Health And Human Services

20120289570 - Compositions and methods for treating and/or preventing cancer by inhibiting fatty acid binding proteins: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.... Agent:

20120289572 - Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype... Agent: Targacept, Inc.

20120289571 - Polymeric conjugates of aromatic amine containing compounds including releasable urea linker: The present invention relates to releasable urea linker systems involving amine-containing chemical compounds and biologically active agents. In particular, the present invention relates to reversibly releasable linkers based on intramolecular cyclization-assisted releasable urea linkages to aromatic amine-containing compounds. The present invention also relates to polymeric conjugates of indolinone-based tyrosine kinase... Agent: Enzon Pharmaceuticals, Inc.

20120289573 - Methods for treatment with bucindolol based on genetic targeting: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor... Agent:

20120289574 - Hydrate crystals: New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal... Agent: Ajinomoto Co., Inc.

20120289576 - Process for forming amorphous atorvastatin: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying... Agent: Pfizer Inc

20120289575 - Topical antimicrobial compositions: Disclosed are topical antimicrobial compositions. The compositions are useful for disinfecting and treating microbial infections of the skin or mucosa of humans and animals. The antimicrobial compositions include a salt of amino acid anion and quaternary ammonium cation, comprising the general formula:... Agent:

20120289577 - Composition for treating or preventing hearing loss comprising naphthoquinone-based compounds: The present invention relates to a composition for treating or preventing hearing loss comprising naphthoquinone-based compounds.... Agent: Kt&g Life Sciences Corporation

20120289587 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel... Agent: Calcimedica, Inc.

20120289588 - Lipase inhibitors for the treatment of pancreatitis and organ failure: The present invention relates to methods for treating pancreatitis and/or organ failure comprising administering, to a subject in need of such treatment, an effective amount of a lipase inhibitor. It is based, at least in part, on the discoveries that lipotoxicity contributes to inflammation, multisystem organ failure, necrotic pancreatic acinar... Agent:

20120289589 - Treatment of immune dysregulation using cannabinoid derivatives: This invention discloses cannabinoid derivatives and pharmaceutical uses thereof.... Agent:

20120289590 - Hair cosmetic composition: A hair cosmetic composition including an exfoliating agent, an antioxidant, and an antibacterial agent. The hair cosmetic composition is noncomedogenic and nonacnegenic.... Agent:

20120289591 - Antimicrobial compositions containing free fatty acids: The invention concerns antimicrobial compositions comprising free fatty acids emulsified with membrane lipids or hydrolysed derivatives thereof, and pharmaceutical formulations comprising same. The compositions can be used in the treatment or prophylaxis of microbial infections. They can also regulate the rate of blood clotting rendering them suitable for incorporation in... Agent:

20120289592 - Ercc1 gene expression level is associated with clinical outcomes in esophageal cancer patients: The disclosure provides compositions and methods for identifying a cancer patient, such as an esophageal cancer patient, suitable for a therapy that includes administration of a platinum drug and radiation pre-operatively, based on the expression level of an ERCC1 gene. After determining if a patient is likely to be successfully... Agent: University Of Southern California

20120289593 - Methods for risk assessment, treating, and diagnosing myocardial infarction: This document features method related to genetic markers associated with myocardial infarction. For example, methods of using such genetic markers for risk assessment and for diagnosing and treating myocardial infarction are provided.... Agent: The General Hospital Corporation

20120289594 - Oral dosage form: An oral dosage form of entacapone and methods for the preparation thereof are provided.... Agent: Orion Corporation

20120289595 - Novel biarylamide derivative and compositions containing the derivative as an active ingredient: The present invention relates to a novel biarylamide derivative and a pharmaceutical composition or a cosmetic composition comprising the same as an active ingredient. More particularly, the present invention relates to a novel biarylamide derivative, a pharmaceutical composition or a cosmetic composition for preventing or treating a pigmentation disorder caused... Agent: Catholic University Industry Academy Cooperation Foundation

20120289596 - Dermatological compositions comprising a fat or oil of an essential fatty acid triglyceride: The present invention relates to a human beta-defensin inducing agent that comprises at least one fat or oil of an essential fatty acid triglyceride or a derivative thereof as the main active ingredient. It also relates to cosmetic, dermatological and pharmacological formulations comprising the at least one fat or oil.... Agent: Croda International PLC

20120289597 - Nitric oxide amino acid esters for the treatment of chronic pain: There is provided a topical composition and a method for treating or alleviating pain in a patient in need thereof. The topical composition contain amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof and a topical analgesic compound.... Agent: Oral Delivery Technology Ltd.

20120289598 - Compositions including pyruvate for companion animals and methods of use thereof: The invention encompasses compositions and methods for treating or preventing a degenerative joint condition, wherein the compositions and methods include feeding the companion animal an edible composition including at least one pyruvate or salt thereof. The invention also encompasses methods for enhancing the palatability of an edible food composition including... Agent: Hill's Pet Nutrition, Inc.

20120289599 - Couplers for medium-chain fatty acids and disinfecting compositions: A disinfecting shower cleaner composition including a medium-chain fatty acid coupled with a nonionic surfactant providing temperature stable antimicrobial compositions. The invention specifically relates to antimicrobial compositions including fatty acid antimicrobial agents coupled with an ethoxylated amine and methods of using the antimicrobial compositions.... Agent: Ecolab Usa Inc.

20120289600 - Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production: Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 50 weight percent of eicosapentaenoic acid [“EPA”], an ω-3 polyunsaturated fatty acid, in the total oil fraction are described. These strains over-express heterologous Δ9 elongases, Δ8 desaturases, Δ5 desaturases, Δ17 desaturases, Δ12 desaturases and C16/18 elongases, and... Agent: E I Du Pont De Nemours And Company

20120289601 - Gastric retained gabapentin dosage form: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.... Agent: Depomed, Inc.

20120289602 - Pharmaceutical composition for treating or preventing burn injuries: The present invention relates to a pharmaceutical composition and the method of use for treating or preventing burn injury in patients or subjects in need, including the compound represented by the specific chemical formula as an active ingredient or its pharmaceutically acceptable salts or solvates.... Agent:

20120289603 - Enhanced bimatoprost ophthalmic solution: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also... Agent: Allergan, Inc.

20120289604 - Pharmaceutical for oral delivery comprising mgbg and methods of treating disease: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.... Agent: Pathologica LLC

20120289605 - Method for inducing udp-glucuronosyltransferase activity using pterostilbene: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.... Agent: Chromadex Inc.

20120289606 - Solid formulations of liquid biologically active agents: The instant invention relates to a solid product comprising a liquid biologically active agent which is intimately associated to a stabilizing agent; particularly a solid product that can be reconstituted to a clear, stable, stabilized nanodispersion or loaded micelles comprising a polymer as a stabilizing agent and a liquid, preferably... Agent:

20120289607 - Absorbent composition and methods thereof: An improved absorbent composition containing biodegradable natural ingredients is described. The composition absorbs liquid quickly, has a large water-absorbing capacity and an excellent water retention capability. The composition enables replacement of a significant amount of less or none biodegradable superabsorbent polymers (SAP) with plant and/or other natural ingredients, while achieving... Agent:

20120289608 - Bone cement and a method for producing same: The invention relates to a bone cement composed of a hydrophilic component and a hydrophobic component, wherein biodegradable material is deposited in pores of the bone cement via the hydrophilic component.... Agent: Aap Biomaterials Gmbh

20120289609 - Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof: The present invention provides both crosslinked polymer compositions capable of forming hydrogels upon exposure to an aqueous environment and thiosulfonate hydrogel-forming components. The thiosulfonate hydrogel-forming components of the invention are preferably multi-arm thiosulfonate polymer derivatives that form a crosslinked polymer composition when exposed to a base without requiring the presence... Agent: Nektar Therapeutics

20120289610 - Oil gel: The present invention relates to the field of oil thickeners and in particular oil gels. Embodiments of the present invention relate for example to a an oil composition containing at least one complex comprising an oil dispersible emulsifier and protein fibres and preparations comprising such oil compositions; the use of... Agent: Nestec S.a.

20120289612 - Composite material and method for producing the same: It has been necessary to use a relatively large amount of cyclodextrin in order to produce a composite material, but the amount of the cyclodextrin needs to be reduced from the viewpoint of costs; in this respect, the present invention provides a composite material comprising a food or active pharmaceutical... Agent: House Foods Corporation

20120289611 - Pectin compounds, methods of using pectin compounds, and methods of controlling water solubility: Briefly described, embodiments of the present disclosure provide for compositions including pectin compounds, pectin compounds, methods of making pectin compounds, methods of controlling the water solubility of a pectin compound, methods of controlling the water solubility of an agent, beads including pectin compounds, and the like.... Agent:

20120289613 - Emulsions, compositions and devices including graphene oxide, and methods for using same: Provided are an emulsion comprising graphene oxide, a first fluid and a second fluid, and a drug delivery system comprising the emulsion. This emulsion is based on the discovery that graphene oxide is an amphiphile with hydrophilic edges and a more hydrophobic basal plane, and thus graphene oxide can act... Agent:

20120289614 - Functionalized biodegradable triclosan monomers and oligomers for controlled release: This invention relates to the discovery of functionalized triclosan monomers and oligomers that, when incorporated into a substrate of, or applied as part of a coating to, medical devices and/or consumer products may extend the duration of antimicrobial properties to the medical devices and/or consumer products.... Agent: Bezwada Biomedical, LLC

  
11/08/2012 > 173 patent applications in 131 patent subcategories. recently filed with US Patent Office

20120283166 - Peptide prodrugs: Provided herein are a novel class of oligopeptides and prodrugs that include amino acid sequences containing cleavage sites for fibroblast activation protein (FAP). Also provided herein are methods of treating FAP related disorders, including cancer.... Agent: The Johns Hopkins University

20120283167 - Ev576 for use in the treatment of viral infections of the respiratory tract: The present invention relates to methods of treating and preventing the inflammatory effects of viral infection of the upper and lower respiratory tracts, including infection by SARS coronovirus (SARS), pandemic Influenza A H5N1 (avian influenza) and pandemic influenza A H1N1 (swine 'flu).... Agent:

20120283168 - Template-fixed peptidomimetics with ccr10 antagonistic activity: Novel template-fixed β-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are α-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property to antagonize the... Agent: Polyphor Ag

20120283169 - Pharmaceutical composition, methods for treating and uses thereof: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the... Agent: Boehringer Ingelheim International Gmbh

20120283170 - Acylated exendin-4 compounds: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.... Agent: Novo Nordisk A/s

20120283171 - Modified bovine somatotropin polypeptides and their uses: Modified bovine somatotropin polypeptides and uses thereof are provided.... Agent: Ambrx, Inc.

20120283172 - Modified porcine somatotropin polypeptides and their uses: Modified porcine somatotropin polypeptides and uses thereof are provided.... Agent: Ambrx, Inc.

20120283174 - Antibiofilm glycopeptides: The present invention relates to peptides and compositions that have antibiofilm properties. In particular, the peptides and compositions of the invention can be used for the treatment or prevention of various conditions including dental caries, gingivitis, periodontitis, oral mucositis, dry mouth and xerostomia.... Agent: Oral Health Australia Pty. Ltd.

20120283173 - Novel compositions for treating pseudomonas infection: The invention relates to a HNK-I mimetic peptide or a polypeptide comprising such HNK-I mimetic peptide for treating or preventing a Pseudomonas infection, in particular an infection with Pseudomonas aeruginosa. The invention further relates to the use of a HNK-I mimetic peptide or a polypeptide comprising such HNK-I mimetic peptide... Agent: Universitatsklinikum Hamburg-eppendorf

20120283175 - Antibacterial compositions: The present invention provides a methods and pharmaceutical compositions useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, a synergistic combination of an inhibitor of LpxC and second antibacterial agent.... Agent: Achaogen, Inc.

20120283176 - Short fatty acid tail polymyxin derivatives and uses thereof: The present invention relates to a polymyxin derivative wherein the derivative has a total of three positive charges at physiological pH and wherein the terminal moiety (D) of the derivative comprises a total of 1 to 5 carbon atoms The invention also relates to a method of treating a subject... Agent:

20120283177 - Novel schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (hiv): The invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in humans, including three or four active principles selected as: a nucleoside reverse transcriptase inhibitor (NARTI) selected from lamivudine and emtricitabine; a nucleoside or nucleotide reverse transcriptase inhibitor (NARTI) selected from didanosine, abacavir and tenofovir; and... Agent:

20120283178 - Learning motivation improvers: e

20120283179 - Pharmaceutical composition comprising a glp-1 agonist and methionine: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.... Agent: Sanofi-aventis Deutschland Gmbh

20120283180 - Pea-based protein mixture and use thereof in a liquid nutritional composition suitable for enteral feeding: This invention relates to a pea-based protein mixture and use thereof in a liquid nutritional composition, in particular suitable for tube feeding, and further relates to said liquid nutritional composition for providing long-term complete enteral nutrition to patients in need thereof. More specifically, the pea-based protein mixture and the liquid... Agent: N.v. Nutricia

20120283181 - Crystal forms of saxagliptin and processes for preparing same: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and... Agent: Bristol-myers Squibb Company

20120283182 - Peptide modulators of the deltapkc interaction with the d subunit of f1f0 atp synthase/atpase and uses thereof: The present invention provides isolated or synthetic peptides derived from the d subunit of mammalian F1Fo ATP synthase (dF1Fo) protein for the purposes of tissue protection and improved energy production following acute injury from ischemia/reperfusion or other toxic insults, or in chronic diseases such as diabetes and cancer. The major... Agent:

20120283183 - Method of reducing cell death by administering a paracrine factor of a mesenchymal stem cell: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.... Agent:

20120283184 - Inhibitors of type 2 vascular endothelial growth factor receptors: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.... Agent: Bristol-myers Squibb Company

20120283185 - Food composition and method of using same: The present invention relates to a food composition preferably for changing body composition and/or physical work capacity. The invention further provides a method of improving body composition and/or physical work capacity. In an aspect of the present invention there is provided a food composition for use in changing the body... Agent: N.v. Nutricia

20120283186 - Therapeutic agent delivery apparatus and process: A method and device to deliver medication in a liquid, gel or suspension formulation to a plurality of adjacent tissue sites of a mammal, the device comprising a plurality of tissue-engaging members for receiving the medication and operably engageable with the plurality of tissue sites; means for supplying the tissue-engaging... Agent: Adams Patent Corporation

20120283187 - Controlled release composition and method of producing the same: A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. A controlled release composition comprising (1) a physiologically active substance or salt thereof in an amount of about 14%... Agent: Takeda Pharmaceutical Company Limited

20120283188 - Genes and proteins associated with angiogenesis and uses thereof: Disclosed is a panel of biomarkers associated with angiogenesis, and the use of such biomarkers (genes, proteins, homologues and analogs thereof) to regulate angiogenesis. Methods for identifying compounds useful for regulating angiogenesis and conditions related thereto are disclosed.... Agent: National Jewish Health

20120283189 - Na-k pump modulation: The present invention relates to a method of modulating Na+/K+ pump activity, the method comprising contacting the Na+/K+ pump with an FXYD protein or a fragment or variant thereof wherein glutathionylation of said Na+/K+ pump is altered by said FXYD protein.... Agent:

20120283190 - Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis: The present invention relates to endothelin inhibitors for use in the treatment of Rapidly Progressive GlomeruloNephritis and to pharmaceutical compositions thereof.... Agent: Institut National De La Sant&#xe9 Et De La Recherche Medicale (inserm)

20120283191 - Approach to treat intraocular hypertension: The present invention relates to the use of antisecretory factors, such as antisecretory proteins, homologues, derivatives and/or fragments thereof having antisecretory activity, for the manufacture of a pharmaceutical composition for use in the treatment and/or prevention of intraocular hypertension. The invention thus relates to the use of pharmaceutical compositions comprising... Agent:

20120283192 - Method of treating conditions associated with airway tissue remodeling: The invention provides a method for improving airway conductance in a subject in need thereof, the method comprising administering to the subject an effective amount of one or more of tumstatin; a derivative, variant or homologue thereof; a polynucleotide encoding tumstatin or a derivative, variant or homologue thereof; or an... Agent: Crc For Asthma And Airways Ltd.

20120283193 - Manipulation of brain in a circuit-specific manner: The present invention relates generally to methods, devices and compositions for treating mental, neurological, and cognitive diseases related to deficiencies in the biosynthesis and/or metabolism of neurotransmitters.... Agent: The Regents Of The University Of California

20120283194 - Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers: Methods and compositions are provided for modulating Hedgehog (Hh) pathway signaling in a cell. Aspects of the methods include methods for inhibiting Hh pathway-promoted cancer proliferation and/or metastasis that is promoted by Hh pathway signaling, methods for treating cancers promoted by Hh pathway signaling, and methods for screening candidate agents... Agent:

20120283195 - Glycopeptide phosphonate derivatives: Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.... Agent: Theravance, Inc.

20120283196 - Beta-hairpin peptidomimetics: β-Hairpin peptidomimetics of the general formula Cyclo(-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-), and pharmaceutically acceptable salts thereof, with Xaa 1-Xaa 16 being amino acid residues of certain types which are defined in the description and the claims, have CXCR4 antagonizing properties and prolonged half-lives in vivo and can be used for preventing HIV infections in... Agent: Polyphor Ag

20120283197 - Compositions comprising a glucose anti-metabolite, bha, and/or bht: A composition including a glucose anti-metabolite, BHA, and/or BHT. The composition can be for a companion animal. The composition can be a nutritionally balanced pet food composition.... Agent:

20120283198 - Halogenated dideoxy sugar derivates, preparation method and application thereof: R1 and R2 are H or Br; R3 and R4 are OH or OAc. The compounds 1-14 of the current invention has strong inhibition effect on human nasopharyngeal cancer CNE-2Z cells, human lung cancer A549 cells. human colon cancer HT-29 cells, human liver cancer Bel-7402 cells, human rectum cancer cells... Agent: Suzhou Harmony Biotechnology Co., Ltd.

20120283201 - 9-substituted minocycline compounds: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and... Agent: Paratek Pharmaceuticals, Inc.

20120283199 - Neuroprotective ganglioside compositions for use in treating or diagnosing huntington's disease: Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of a polyglutamine stretch in the protein huntingtin (Htt). HD neurons are dysfunctional at multiple levels and have increased susceptibility to stress and apoptotic stimuli. As described therein there is provided compound(s), composition(s), methods and/or kits for the treatment... Agent: The Governers Of The University Of Alberta

20120283200 - Pharmaceutical composition and method for preventing or treating chronic heart disease: n

20120283202 - Anti-wart pharmaceutical composition and method for treating wart: Disclosed herein is an anti-wart pharmaceutical composition including a water-soluble extract from a plant of Solanum genus, the water-soluble extract comprising solamargine and solasonine. Also disclosed is a method for treating wart including applying to a subject in need of such treatment the water-soluble extract.... Agent: G & E Herbal Biotechnology Co., Ltd.

20120283203 - Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia: A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient.... Agent: Board Of Trustees Of Michigan State University

20120283204 - Talarazole metabolites: Novel metabolites of talarazole of formula (I) have been isolated and characterized, wherein R═H, OH, OSO3H or O-gly; R1, ═H, OH, OSO3H, O-gly or =0; and gly=a glucuronate, or a pharmaceutically acceptable salt thereof. These compounds are targeted for the treatment of various skin-, hair- and nail-associated disorders.... Agent:

20120283205 - Compositions and methods of delivery of pharmacological agents: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of... Agent:

20120283206 - Combination comprising n--4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.: A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute... Agent:

20120283207 - Antibacterial aminoglycoside analogs: m

20120283208 - Antibacterial aminoglycoside analogs:

20120283209 - Antibacterial aminoglycoside analogs:

20120283210 - Maribavir isomers, compositions, methods of making and methods of using: The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.... Agent:

20120283313 - Inhibition and treatment of prostate cancer metastasis: The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.... Agent: Northwestern University

20120283310 - Microrna signatures associated with human chronic lymphocytic leukemia (cll) and uses thereof: Methods and compositions for the diagnosis, prognosis and/or treatment of leukemia associated diseases are disclosed.... Agent:

20120283312 - Modulation of eif4e expression: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with... Agent: Isis Pharmaceuticals, Inc.

20120283309 - Sirna compounds comprising terminal substitutions: The invention relates to modified siRNA compounds which down-regulate target gene expression, to pharmaceutical compositions comprising such compounds and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions.... Agent:

20120283311 - Sirna targeting glucagon receptor (gccr): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Dharmacon, Inc.

20120283314 - Sodium channel protein type iii alpha-subunit splice variant: The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same.... Agent: Vertex Pharmaceuticals Incorporated

20120283316 - Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers: Disclosed are drug delivery compositions comprising an oligonucleotide-modified nanoparticle and a therapeutic agent. Specifically, disclosed are compositions comprising a number of oligonucleotide molecules in a ratio to therapeutic agent molecules to allow a sufficient transportation of the therapeutic agent molecules into a cell. The therapeutic agents include both hydrophobic and... Agent: Northwestern University

20120283317 - Methods and compositions for regulating rna import into mitochondria: Disclosed herein recombinant and/or isolated nucleic acid molecules which comprise, consist essentially of, or consist of a first nucleic acid sequence, which is a wild-type sequence or an altered sequence, directly or indirectly linked to a second nucleic acid sequence selected from the group consisting of: (1) a mitochondria localization... Agent:

20120283319 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment... Agent: Regulus Therapeutics Inc.

20120283318 - Replicating viral vectors for gene therapy: The present invention concerns the field of gene therapy and in particular the use of specific adenoviral vector systems for gene therapy, said vector systems offering enhanced efficiency and specificity for gene delivery. More specifically, the present invention provides replicating-competent adenoviral vector systems carrying one or more inserted heterologous gene.... Agent:

20120283315 - Sdf-1 delivery for treating ischemic tissue: A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left... Agent:

20120283211 - Medical implants containing adenosine receptor agonists and methods for inhibitiing medical implant loosening: The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A2A receptor, in particular, an agonist of an adenosine A2A receptor. The invention... Agent:

20120283213 - Aryl/alkyl succinic anhydride hyaluronan derivatives: The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties... Agent: Novozymes Biopolymer A/s

20120283212 - Use of polysaccharides for treating stress and anxiety: The present invention relates to a composition including a mix of a polysaccharides having: 15% to 50% of glucoside linkages 1-6; a reducing sugar content of less than 20%; a polymolecularity index of less than 5; an average molecular weight with number Mn of less than 4500 g/mole and at... Agent: Roquette Freres

20120283214 - Cyclodextrin-based polymers for therapeutics delivery: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from... Agent: Cerulean Pharma Inc.

20120283215 - Pharmaceutical compositions which inhibit fkbp52-mediated regulation of androgen receptor function and methods of using same: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and... Agent: Health And Human Services

20120283216 - Fungicidal 2-(bicyclic aryloxy)carboxamides: a

20120283217 - Modulators of amyloid-beta production: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition... Agent: Satori Pharmaceuticals, Inc.

20120283218 - Modifications of solid 3-sn-phosphoglycerides: Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.... Agent: Biomolecular Products, Inc.

20120283220 - Antofine and cryptopleurine derivatives as anticancer agents: The present invention provides compounds of Formula (I-IV): compositions containing the same, and methods of use thereof such as for the treatment of cancer.... Agent:

20120283219 - Diaminopteridine derivatives: The present invention relates novel diaminopteridine derivatives, their compositions and method of treatment comprising the same for use as anti-infectives.... Agent:

20120283221 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent:

20120283222 - Heteroarylcarboxylic acid ester derivative: e

20120283223 - Cerebral nerve cell neogenesis agent: An objective of the present invention is to provide a new substance having a cerebral nerve cell neogenesis effect. Another objective is to provide a cerebral nerve cell neogenesis agent that is effective in treating and/or preventing neurological disorders utilizing the substance. With the present invention, a cerebral nerve cell... Agent:

20120283224 - Chemical structure comprising phosphates with polyol substructures for hair and skin cosmetics usage: A composition suitable for application to hair and/or skin comprises Phosphates Esters, such as Xylitol Phosphate Esters and other Polyol Units Phosphoric Acid Esters. This composition can be used to improve or treat skin, including scalp, conditions in cosmetic or pharmaceutical products for acne, dandruff, seborrheic dermatitis and malodor and/or... Agent: Chemyunion Quimica Ltda

20120283225 - Combination therapy for skin disorders: The present invention provides a novel therapeutic combination comprising one or more anti-androgen agents and one or more antibiotic/anti-inflammatory agents or pharmaceutically acceptable salts or hydrates thereof, useful for the treatment of a dermatological disorder.... Agent: M. Alphabet 1,. LLC

20120283226 - Cosmetic composition: A dermatological or cosmetic composition for skin care which includes the salt of an α-hydroxy acid, β-hydroxy acid, poly hydroxy acid or bionic acid in combination with niacinamide.... Agent: Reckitt Benckiser Healthcare International Limited

20120283227 - (20s)-24-(p-toluenesulfonyloxy)-25,26,27-trinorvitamin d3 analogs and their uses: This invention discloses (20S)-24(p-toluenesulfonyloxy)-25,26,27-trinorvitamin D3 analogs, and especially (20S)-25,26,27-trinor-24-(p-methylphenylsulfonate)-vitamin D3, its biological activities, and pharmaceutical uses therefor. This compound exhibits relatively little calcemic activity and does not promote cellular differentiation of HL-60 leukemia cells, but rather kills the cells. This cell death activity is found in small cell lung carcinoma... Agent: Wisconsin Alumni Research Foundation

20120283228 - 2alpha-methyl and 2beta-methyl analogs of 19,26-dinor-1alpha,25-dihydroxyvitamin d3 and their uses: This invention discloses 2α-methyl and 2β-methyl analogs of 19,26-dinor-1α,25-dihydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit in vitro biological activities evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and... Agent: Wisconsin Alumni Research Foundation

20120283229 - 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties: The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzodiazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat... Agent: The Regents Of The University Of Michigan

20120283230 - Pharmaceutical compositions: Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance,... Agent: Endorecherche, Inc.

20120283231 - Delivery of corticosteroids through iontophoresis: Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.... Agent: Eyegate Pharmaceuticals, Inc.

20120283233 - Carrier composition: The present invention relates to a carrier composition comprising a phosphate compound of an electron transfer agent and a polar aprotic solvent. Biologically active compounds formulated with the carrier composition have been shown to have improved properties.... Agent:

20120283232 - Process for making a pharmaceutical composition: Process for making a sterile, injectable pharmaceutical composition by combining triamcinolone, a buffer and a high viscosity hyaluronate.... Agent:

20120283234 - Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions: o

20120283235 - Dermatologic and cosmetic compositions: Provided are compositions and methods for treatment of conditions and diseases of the skin, for example fine lines and wrinkles and rosacea. The compositions include a porphyrin that is a chlorophyllin, a chlorin compound, a complex of a chlorin compound, or a salt or ester of the chlorin compound or... Agent: Discovery Partners LLC

20120283236 - Porphyrin catalysts and methods of use thereof: This invention provides a novel class of substituted macrocyclic porphyrin compounds. The compounds are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof are also described.... Agent:

20120283237 - Novel cephalosporins useful as antibacterial agents: i

20120283239 - 1h-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives: The invention relates to 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derived Cathepsin S inhibitors of Formula (I), wherein R1 is H or (C1-3)alkyl; R2 is halogen or (C1-4)alkyl, optionally substituted with one or more halogens; n is 1-3; X is O or CH2; U, V and W are CH; or one of U, V and... Agent: Msd Oss B.v.

20120283240 - Analogs of indole-3-carbinol and their use as agents against infection: Compounds useful as antibacterial agents are provided. The compounds are analogs of indole-3-carbinol and have a backbone selected from dihydroindolo[2,3-b]carbazole, 2,2′-diindolylmethane, 2′,3-diindolylmethane, and 3,3′-diindolylmethane. The compounds are useful therapeutic and prophylactic treatment of bacterial infections in mammals. Methods of synthesis of the compounds are provided, as are pharmaceutical compositions containing... Agent:

20120283241 - Imidazopyridazinecarbonitriles useful as kinase inhibitors: m

20120283238 - Irak inhibitors and uses thereof: The present invention provides compounds, compositions thereof, and methods of using the same.... Agent: Nimbus Iris, Inc.

20120283242 - Di - substituted pyridine derivatives as anticancers: The present invention provides a novel compound having an excellent antitumor effect. The compound of the present invention is represented by the following general formula (1) wherein R1 and R2 are aryl or the like; A is lower alkylene; Ring X is optionally substituted arylene; E is bond or lower... Agent:

20120283243 - Spiroindoline modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Vertex Pharmaceuticals Incorporated

20120283244 - Association between 4-benzamide and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing it: e

20120283245 - Azabicyclo[3.1.0]hex-2-yl compounds, a process for their preparation and pharmaceutical compositions containing them:

20120283246 - Novel parenteral carbamazepine formulation: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are... Agent:

20120283247 - Diazepane acetamide derivatives as selective 11b-hsd1 inhibitors: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension... Agent: Merck Patent Gmbh

20120283248 - Composition and method for treating cognitive impairments in down syndrom subjects: Compounds having inverse agonist functional selectivity for GABAA receptors containing the α5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The use of these compounds is disclosed. Pharmaceutical compositions for such treatment can comprise these compounds or suitable pharmaceutically acceptable... Agent: Centre National De La Recherche Scientifique - Cnrs

20120283250 - Methods and compositions for determining hypersusceptibility of hiv-1 to non-nucleoside reverse transcriptase inhibitors: This invention relates to methods for determining hypersusceptibility of HIV-1 viruses to non-nucleoside reverse transcriptase inhibitors (NNRTIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding reverse transcriptase of the HIV-1, the presence of a mutation at codon 65, 69, or 74 alone or in... Agent: Monogram Biosciences, Inc.

20120283249 - Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action: The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as, for example, ricin, and of viruses that use the... Agent:

20120283251 - Deuterated 5,6-dihydro-1h-pyridin-2-one compounds: The invention is directed to deuterated 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Anadys Pharmaceuticals, Inc.

20120283252 - Process for preparing pharmaceutical ophthalmic compositions: Pharmaceutical ophthalmic compositions comprising active ingredient(s) such as carbonic anhydrase inhibitor (CAI) or combinations and processes for making such compositions and the use of these compositions in patient populations including pediatric populations. A process for preparing an ophthalmic composition comprising a carbonic anhydrase inhibitor, which comprises a) preparing a slurry... Agent: Lupin Limited

20120283253 - Semi-solid delivery vehicle and pharmaceutical compositions: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.... Agent: A.p. Pharma, Inc.

20120283254 - Novel benzofurane-piperidine compounds: s

20120283255 - Urea derivatives, methods for their manufacture, and uses therefor:

20120283256 - New heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the app metabolism occurs: The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.... Agent:

20120283257 - Pharmaceutical compounds: wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such... Agent: F. Hoffmann-la Roche Ag

20120283260 - Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma: The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.... Agent: Alcon Research, Ltd.

20120283258 - Mediators of hedgehog signaling pathways, compositions and uses related hereto: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize... Agent: Genentech, Inc.

20120283259 - Novel inhibitors: Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.... Agent: Probiodrug Ag

20120283261 - Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase: In one aspect, the invention relates to substituted N-phenylpyrimidin-2-amine analogs, derivatives thereof, and related compounds, which are useful as inhibitors of Axl kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions for treating disorders associated with dysfunction of the... Agent:

20120283262 - Pharmaceutical compositions comprising sigma receptor ligands:

20120283263 - Triazine-aryl-bis-indoles and process for preparation thereof: A novel heterocyclic compound belonging to ‘triazine-aryl-bis-indoles’, useful for the treatment of asthma. The pathway by which this compound inhibits asthma is also demonstrated. The present invention also provides a process for the preparation of above compounds and their derivatives are presented.... Agent: Council Of Scientific & Industrial Research

20120283265 - Compounds useful for treating aids: The present invention relates to compound Formula (I) wherein: Formula (II) means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a CN group, a hydroxyl group, a COOR1 group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group, a... Agent: Centre National De La Recherche Scientifique

20120283264 - Oxazolidinones as modulators of mglur5: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.... Agent: Bristol-myers Squibb Company

20120283266 - Lysine specific demethylase-1 inhibitors and their use: The invention relates to a compound of Formula (I): (A′)x-(A)-(B)-(Z)-(L)-(D), wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen... Agent:

20120283267 - Compositions and methods for the treatment of giardiasis: Methods of treating exposure to Giardia lamblia and/or giardiasis and methods of antagonizing Giardia lamblia attachment to the intestinal wall of a subject are described herein.... Agent: Georgetown University

20120283268 - Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers: Thiazole and thiophene compounds are disclosed having utility in treating inflammatory conditions, immunoinflammatory conditions, autoimmune diseases, and cancers. Methods for the synthesis of these compounds are also disclosed.... Agent:

20120283269 - Method and compositions for suppression of aging: The present invention provides a method of suppression and/or deceleration of mammalian cellular aging. The method involves contacting mammalian cells with a composition that contains a non-genotoxic inducer of p53 (NGIP). In certain embodiments, the NCIP is a Mdm-binding agent or Mdm-2 antagonist. The NGIP can be nutlin, nutlin-3A, a... Agent: Health Research Inc.

20120283270 - Extracts and beverages containing 2,5-piperazinedione,3,6-bis(phenylmethyl)-, (3s,6s)-: The present invention aims to provide extracts or beverages containing 2,5-piperazinedione,3,6-bis(phenylmethyl)-,(3S,6S)—, which is a useful substance with an improving effect on learning motivation, in an easy-to-ingest form and at a high concentration. Extracts or beverages whose ratio between the content of 2,5-piperazinedione,3,6-bis(phenyl-methyl)-,(3S,6S)— (unit: μg/100 g) and Brix(Bx) is 6 (μg/100... Agent: Suntory Holdings Limited

20120283272 - Compounds for inflammation and immune-related uses: The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent: Synta Pharmaceuticals Corp.

20120283271 - Isoindolinone derivatives: as well as pharmaceutically-acceptable salts thereof, pharmaceutical compositions containing said compounds and methods of using said compounds in the treatment or prophylaxis of diseases and disorders. The compounds and compositions disclosed herein are glucokinase activators useful for the treatment or prophylaxis of metabolic diseases and disorders, for example diabetes mellitus,... Agent:

20120283273 - Indole and azaindole modulators of the alpha 7 nachr: This invention relates to modulation of the α7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I) or a pharmaceutically acceptable salt thereof.... Agent: Proximagen Limited

20120283274 - Crystalline forms of substituted pyrazolopyrimidines: The present invention relates to novel co-crystals of pyrazolopyrimidines and a co-crystal former, wherein the co-crystal former is an organic carboxylic acid, preferably selected from the group of gentisic acid, succinic acid and xinafoic acid.... Agent:

20120283275 - Methods and dosage forms for reducing side effects of benzisozazole derivatives: Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.... Agent:

20120283276 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120283277 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120283278 - Combination: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt... Agent:

20120283279 - Combination: A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a mTOR inhibitor, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or mTOR is beneficial, e.g. cancer.... Agent: Glaxosmithkline LLC

20120283280 - Imidazotetrazinone-based combi-molecules: A series of new chemical agents that demonstrate anti-tumor activity are described herein. The new chemical agents exhibit a dual mode of anti-tumor action: blocking epidermal growth factor receptor (EGFR) mediated signal transduction and damaging DNA by alkylation.... Agent:

20120283281 - New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents: The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamide, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent.... Agent:

20120283282 - Photoproducts of tryptophan, their synthesis and uses thereof: We have found that exposure of an aqueous tryptophan solution to window sunlight results in the production of multiple tryptophan photoproducts that have the capability of activating the aryl hydrocarbon receptor and increasing the production of AhR target genes and proteins in hepatocytes. We have isolated three of those photoproducts... Agent:

20120283283 - Methods for detecting enhanced risk of opioid-induced hypoxia in a patient: Methods for detecting enhanced risk of opioid-induced respiratory dysfunction in patients with normal levels of oxygen saturation. The method may comprise: (1) assaying blood of the patient for a normal level of oxygen saturation; (2) measuring the patient's respiration rate at rest for a normal rate; and (3) correlating the... Agent:

20120283284 - Melonine bisindole compounds, pharmaceutical compositions, preparation method and use thereof: The present invention relates to pharmaceutical technical field, to melonine bisindole compounds, pharmaceutical compositions thereof, and preparation methods thereof. Specifically, the present invention relates to melonine bisindole compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof. The present invention further relates... Agent: Kunming Institute Of Botany, The Chinese Academy Of Sciences

20120283285 - Treatment of solid tumors with rapamycin derivatives: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.... Agent:

20120283286 - Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy: Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to... Agent: Medicis Pharmaceutical Corporation

20120283287 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent:

20120283288 - 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS... Agent: Cancer Research Technology Limited

20120283289 - Crystalline form of a biphenyl compound: The invention provides a crystalline 1,2-ethanedisulfonic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also provides pharmaceutical compositions comprising such a salt or prepared using such a salt; processes and intermediates for preparing such a salt; and methods of using such a salt to treat... Agent: Theravance, Inc.

20120283290 - Quantitation of gl3 in urine: The present invention is directed to the quantitation of GL3 in human urine which can be used for the diagnosis of Fabry disease as well as for the assessment of treatment efficacy thereof.... Agent: Amicus Therapeutics Inc.

20120283291 - Solid pharmaceutical composition comprising donepezil hydrochloride: The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms.... Agent: Krka, Tovarna Zdravil D.d., Novo Mesto

20120283292 - Fatty acid lenalidomide and their uses: The invention relates to fatty acid lenalidomide derivatives; compositions comprising an effective amount of a fatty acid lenalidomide derivative; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid lenalidomide derivative.... Agent:

20120283293 - Methods of neuroprotection involving prostaglandin e2 ep4 (pge2 ep4) receptor activation: The present invention provides methods for attenuating neuronal inflammation and neuronal damage in case of acute or chronic injury of nerve cells of the central nervous system through prostaglandin E2 EP4 receptor activation. Methods for treating neuropathic pain are also provided.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120283294 - Co-crystal of 4-furan-2(5h)-one with benzoic acid and use thereof as pesticide: The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino} furan-2(5H)-one with benzoic acid, to processes for the preparation thereof and use thereof.... Agent: Bayer Technology Services Gmbh

20120283295 - Indazole derivatives and their use for blockading voltage dependent sodium channels: The invention provides an indazole derivative of formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, wherein R1, R2, R3 and R4 are as defined herein. The indazole derivatives are capable of blockading voltage dependent sodium channels and they are useful in the treatment or prevention of normal tension... Agent: University College London

20120283297 - Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists: Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.... Agent: Glaxo Wellcome House

20120283296 - Pyrrolopyrazoles for treating cns disorders: Provided herein are methods of utilizing PAK inhibitors for the treatment of CNS disorders.... Agent: Afraxis, Inc.

20120283298 - Methods for treating memory impairment: Methods for administering a therapeutically effective amount of a somatostatin receptor-4 (SSTR4) agonist in order to treat learning and memory impairment for Alzheimer's disease is disclosed.... Agent:

20120283299 - Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and... Agent: Hanall Biopharma Co., Ltd.

20120283300 - Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis: This application relates to a novel benzo-heterocycle derivative and more particularly, it relates a composition for preventing and treating cancer or for inhibiting metastasis comprising benzo-heterocycle derivative or pharmaceutically acceptable salts thereof as an active ingredient. The present inventors confirmed that KRS has an effect on cancer metastasis by facilitating... Agent: Snu R&db Foundation

20120283301 - S-triazolyl alpha-mercapto acetanilides as inhibitors of hiv reverse transcriptase: A series of S-triazolyl α-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.... Agent: Ardea Biosciences Inc.

20120283302 - Scca-1 production inhibitor having a carboxamide derivative and/or a salt thereof as an active ingredient: wherein X is CR5 or N, R1, R4 and R5 each independently represent hydrogen, C1-C4 alkyl or a C1-C6 hydroxyalkyl group having 1-5 hydroxy groups, R2 and R3 each independently represent hydrogen, C1-C4 alkyl or a C1-C6 hydroxyalkyl group having 1-5 hydroxy groups, or each represents a group —(CH2)n—, wherein... Agent: Shiseido Company, Ltd

20120283303 - Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases: The present invention relates to the use of N-aminoimidazole or N-aminoimidazole thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes.... Agent: K.u.leuven Research And Development

20120283304 - Formulations of temozolomide for parenteral administration: The present invention relates to a parenteral formulation of Temozolomide comprising an excipient selected from the group consisting of bulking agents, buffers, pH adjusting agents, with the proviso that the formulation is free of dissolution enhancing agents.... Agent: Sahaj Life Sciences Pvt. Ltd.

20120283305 - Cysteine protease inhibitors: e

20120283306 - Mouse model for avm: Arteriovenous malformation, or Arteriovenous vascular malformation (AVM) is a congenic disorder characterized by an abnormal connection between veins and arteries, resulting in hemorrhaging and even death. A lack of good animal models has long been an obstacle for identifying effective drugs for neurological AVM treatment. Describe herein is a mouse... Agent: Georgia Health Sciences University

20120283307 - Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels: A method of treating insulin resistance, obesity and metabolic syndrome by administering an indazolemethoxyalkanoic acid as described herein.... Agent: Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

20120283308 - Animal feed composition: Disclosed is an animal feed composition that comprises free indole acetic acid (free IAA) or a derivative thereof. Also disclosed is a method for enhancing animal growth by feeding the animal with a composition according to the invention. Further disclosed is the use of free IAA or a derivative thereof... Agent:

20120283320 - Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities: The present invention relates to oral nutritional and therapeutic products which are useful for preventing or treating compensated and decompensated insulin resistance and associated diseases and sequelae, or diabetes mellitus and its sequelae, complications, and co-morbidities, comprising magnesium R-(+)-alpha-lipoate.... Agent: Biolink Life Sciences, Inc.

20120283321 - Use of gambierol for treating and/or preventing neurodegenerative diseases related to tau and beta-amyloid: e

20120283322 - Rhus verniciflua stokes extract having increased content of active flavonoid compound and method for preparing same: The present invention relates to Rhus verniciflua Stokes extract having an increased content of an active flavonoid compound through a gas bubbling treatment, a method for preparing the Rhus verniciflua Stokes extract, and a method for converting fustin into fisetin through the gas bubbling treatment of a solution containing fustin.... Agent: Azi Company Ltd.

20120283323 - Treating learning deficits with inhibitors of hmg coa reductase: The disclosure provides methods of treating cognitive disorders by administering a HMG CoA reductase inhibitor. Cognitive deficits treatable with the inhibitor compound include those associated with Angelman Syndrome, Neurofibromatosis-1, certain forms of X-linked mental retardation, tuberous sclerosis, Down Syndrome, autism, and attention deficit/hyperactivity disorder.... Agent:

20120283324 - Antagonists and agonists of bitter taste receptors and uses thereof: The present invention relates to antagonists and agonists of the human bitter-taste receptors hTAS2R40, hTAS2R43, hTAS2R44, hTAS2R46, and hTAS2R47. The invention also relates to methods for identifying further molecules that suppress or enhance bitter taste transduction or bitter taste response mediated by hTAS2R40, hTAS2R43, hTAS2R44, hTAS2R46, and/or hTAS2R47 and uses... Agent: Deutsches Institut Fur Emahrungsforschung Potsdam-rehbrucke

20120283325 - Excipient compatibility with ezatiostat: Disclosed herein is the surprising and unexpected discovery that mannitol inhibits the growth of impurities and enhances shelf life of ezatiostat hydrochloride formulations.... Agent: Telik, Inc.

20120283326 - Anthranilic acid derivatives: Compounds of formula (I) are provided, wherein X is CH═CH, CH2O wherein the oxygen atom is bound to ring B, or OCH2 wherein the oxygen atom is bound to ring A; Y is hydrogen, straight or branched C1-C6 alkyl or a pharmaceutically acceptable inorganic cation; R1 is ethyl or cyclopropyl;... Agent: Chelsea Therapeutics, Inc.

20120283327 - Pharmaceutical compositions and therapeutic applications of a hydrocortisone derivative designated as deina: The hydrocortisone derivative of formula (I), whose IUPAC name is 3-[3,5-Dihydroxy-3-(2-hydroxy-acetyl)-3a,6-dimethyl-7-oxo-dodecahydro-cyclo-penta[alpha]naphthalen-6-yl]-propionic acid, designated as Deina®, is used in the treatment of atrophic tissues, particularly skin, cartilage, connective, and mucosal tissues and scalp skin.... Agent:

20120283328 - Photosensitizer composition for treating skin disorders: A composition comprising an active ingredient selected from the group of 5-aminolevulinic acid or a pharmaceutically acceptable salt or derivative thereof; and an aqueous carrier comprising at least one absorption enhancer, an anesthetic, hyaluronic acid and at least one acid selected from the group consisting of glycolic acid and lactic... Agent:

20120283329 - S isomers of alpha-methyl hydrocinnamic acid for the treatment of blood disorders: The present intervention generally relates to compositions comprising S-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising S-isomer of alpha-methyl-hydrocinnamic acid to the subject to... Agent:

20120283330 - Methods for the treatment of dermatological disorders: e

20120283331 - Anti-inflammatory quinic acid derivatives for radioprotection/radiomitigation: Disclosed are methods of use of analogs of quinic acids or shikimic acids for protection from the harmful effects of radiation when administered either prior to radiation exposure, after radiation exposure, or both. These methods are useful for treating humans and animals exposed to radiation and at risk for radiation... Agent: University Of Tennessee Research Foundation

20120283333 - Ophthalmic compositions with an amphoteric surfactant, hyaluronic acid and polyquaternium-1: wherein R1 is R or —(CH2)n-NHC(O)R, wherein R is a C8-C30alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R2 and R3 are each independently selected from the group consisting of hydrogen and C1-C4alkyl; R4 is a C2-C8alkylene optionally substituted with hydroxyl; and Y is CO2− or... Agent:

20120283332 - Transdermal delivery of metformin: Provided is a transdermal metformin that is an effective alternative treatment modality in patients with insulin resistance. Transdermal metformin can be used in conditions where oral metformin is indicated such as Type 2 diabetes mellitus, pre-diabetes, polycystic ovarian syndrome, and other known diabetes associated disorders. One advantage of using transdermal... Agent: Ohio University

20120283334 - Treatment of viral infections: The invention provides compositions, medicaments and methods of treatment of viral infections, especially respiratory disorders caused by viral infections. In particular, the invention relates to the treatment of acute viral infections using a range of related 1-phenyl-2-amino ethanol, ethanal, and ethane derivatives.... Agent: Biocopea, Ltd.

20120283335 - Analogs of propofol, preparation thereof and use as anesthetics: Compounds of formula (I) wherein X is H or F and pharmaceutically acceptable salts thereof are useful as anesthetics.... Agent:

20120283336 - Preparation of shaped metal particles and their uses: The instant invention relates to shaped transition metal particles, in particular in the form of a dispersion in an aqueous and/or organic medium, the manufacture thereof and their use as an infrared (IR) absorbing agent, an IR curing agent for coatings, an additive in conductive formulations, an antimicrobial agent or... Agent: Basf Se

20120283337 - Inorganic porous particles with stabilized micropores: Sol-gel inorganic porous particles can be formed with two set of pores with different average sizes. These inorganic porous particles are composed of an inorganic compound that provides an inorganic solid phase including an external particle surface. They also have a first set of pores wherein the pores have an... Agent:

20120283338 - Sweetener compositions and methods of making the same: Disclosed is a method of preparing a composition by mixing a sweetener and an ingredient, pressing the sweetener and ingredient together to form a pressed mixture in the form of a sheet, briquette, pellet, flake or other form, and reducing the pressed mixture to yield a composition. The composition comprises... Agent: Cargill ,incorporated

  
11/01/2012 > 185 patent applications in 132 patent subcategories. recently filed with US Patent Office

20120277142 - Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.... Agent: Hanall Biopharma Co., Ltd.

20120277143 - Il4/il13 binding repeat proteins and uses: IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpaha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as... Agent:

20120277144 - Novel compounds for modulating neovascularisation and methods of treatment using these compounds: The invention relates to a method for modulating neovascularisation of a tissue in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound or a combination of compounds selected from an isolated nucleic acid molecule comprising a gene selected from the... Agent:

20120277145 - Compounds: The present invention pertains generally to certain compounds of the deoxyactagardine A and B type. Such compounds are suitable for use in the treatment of microbial infections, for example Clostridium infection, such as C. perfringens, C. difficile, C. tetani, and/or C. botulinum, in particular C. difficile, especially infection of the... Agent:

20120277146 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Onyx Pharmaceuticals Inc.

20120277147 - Prevention of hypoglycaemia in diabetes mellitus type 2 patients: A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and (b) a sulfonyl urea or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.... Agent: Sanofi-aventis Deutschland Gmbh

20120277148 - Insulin analogues with chlorinated amino acids: An insulin analogue comprises a B-chain polypeptide incorporating a chlorinated phenylalanine. The chlorinated phenylalanine may be located at position B24. The chlorinated phenylalanine may be para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The chlorinated insulin analogues... Agent: Case Western Reserve University

20120277149 - Pharmaceutical combinations for the treatment of metabolic disorders: The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose... Agent: Boehringer Ingelheim International Gmbh

20120277150 - Novel 3-hydroxyisothiazole 1-oxide derivative: (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is 0 or —NR7—;... Agent: Mochida Pharmaceutical Co., Ltd.

20120277151 - Glp-1 pharmaceutical compositions: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.... Agent: Ipsen Pharma S.a.s.

20120277152 - Compressed high density fibrous polymers suitable for implant: An embodiment of the present invention may be made by the following steps: providing a mixture comprising a plurality of fibers, a lubricant, and a suspension fluid, with the suspension fluid filling a void space between said fibers and subjecting said mixture to at least one compressive force. The compressive... Agent:

20120277153 - Treating liver diseases: This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided.... Agent: Mayo Foundation For Medical Education And Research A Minnesota Corporation

20120277154 - Homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof: Provided is a homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof, wherein the insulinotropic peptide analogue comprises GLP-1 and Exendin-4. The homodimer of insulinotropic peptide analogues of the invention is made by conjugating two identical insulinotropic peptide analogue molecules at the C-terminal Cys residues via... Agent: Chongqing Fagen Biomedical Inc.

20120277155 - Therapy for kidney disease and/or heart failure: Medical systems and methods for treating kidney disease alone, heart failure alone, chronic kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a natriuretic peptide such as Vessel Dilator to a subject. Methods for increasing and maintaining peptide levels... Agent: Medtronic, Inc.

20120277156 - Inhibition of pathological bone formation: Described are methods of inhibiting heterotopic ossification (HO) in a subject in need thereof. The methods involve administering an effective amount of a proprioception inhibitor to the subject, whereby HO is inhibited or prevented. The present invention also relates to a method of treating a subject with bone trauma. This... Agent: University Of Washington Trhough It's Center For Commercialization

20120277157 - Disease treatment via antimicrobial peptides or their inhibitors: Provided are methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. Also provided... Agent:

20120277158 - Compositions and methods for the transport of therapeutic agents: The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to... Agent: Angiochem Inc.

20120277159 - Methods for treating depression using ncam peptide mimetics: The present application relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder and schizophrenia. The invention provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds which are useful for treating patients who suffer... Agent: Board Of Trustees Of The Leland Stanford Junior University

20120277160 - Composition for improving brain function and method for improving brain function: Provided are a composition for improving the brain function, which can be orally taken at a low dose, and a method therefor. The composition for improving the brain function contains, as the active ingredient, X-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (wherein X is nil or represents Ile or Asn-Ile; and Y is nil or represents... Agent:

20120277161 - Inhibition of multiple cell activation pathways: There is provided a method for inhibiting growth and/or proliferation of a cancer cell. The method comprises treating a cancer cell with an effective amount of a polypeptide providing a cytoplasmic binding domain of a β integrin subunit for binding of ERK2 to inhibit at least one protein kinase, other... Agent: Inter-k Pty Limited

20120277163 - Microrna-10 antagonists and microrna-10 targets for use in the treatment of a glioma: The present invention embraces microRNA-antagonists and activators of homeobox D10 protein; Zinc finger, MYND domain containing 11 protein; or RB1-inducible coiled-coil 1 protein for use in decreasing glial tumor cell proliferation and treating glioma.... Agent: Trustees Of Dartmouth College

20120277162 - Polypeptide compounds for inhibiting angiogenesis and tumor growth: In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.... Agent: Vasgene Therapeutics, Inc.

20120277164 - Gadd45beta targeting agents: Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders.... Agent: Imperial Innovations Limited

20120277165 - Methods of modulating fucosylation of glycoproteins: The present invention provides methods and materials useful for monitoring and regulating the glycosylation of glycoproteins that are recombinantly produced from cells. In particular, methods are provided for monitoring and regulating levels of cellular indicators which affect the level of fucosylation produced by cells.... Agent:

20120277166 - Conotoxin peptides useful as inhibitors of neuronal amine transporters: The invention relates to an isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.... Agent: Xenome Limited

20120277167 - Oral formulations of glycyl-2-methylprolyl-glutamate: Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an... Agent:

20120277168 - Kokumi-imparting agent: A substance capable of imparting a kokumi having CaSR agonist activity is described. This substance is able to impart kokumi in a superior manner, in particular, at the initial taste, and is also highly stable and can easily be produced at a low cost. The present invention thus provides a... Agent:

20120277170 - Nutritive compositions and methods of using same: The invention provides intradialytic parenteral nutrition (IDPN) compositions with low carbohydrate for the treatment of malnutrition in dialysis subjects. In some embodiments, the IDPN compositions are advantageous for the treatment of malnutrition in subjects who are diabetic or suffer from other glucose management related pathologies or subjects who benefit from... Agent: Pentec Health, Inc.

20120277169 - Nyasol and analogs thereof for the treatment of estrogen receptor beta-mediated diseases: Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor... Agent: Bionovo, Inc.

20120277171 - Warmi®, natural alternative for the treatment of menopause: Warmi®, composed of glucosinolates, β-sitosterol and citrus flavonoids (hesperidin), is as effective as HRT in reducing menopausal symptoms, Warmi® promotes a healthy cardiovascular system, supports hormonal balance and emotional well-being, improving the quality of life of women during perimenopause and menopause. All of these and the lack of side effects... Agent:

20120277172 - Carbohydrate-lipid constructs and their use in preventing or treating viral infection: The invention relates to selected carbohydrate-lipid constructs and their use as mimics of ligands for receptors expressed by a virus. In particular, the invention relates to the use of selected carbohydrate-lipid constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects. Carbohydrate-lipid constructs selected for... Agent: Kode Biotech Limited

20120277173 - Stabilized anthocyanin compositions: The invention describes stabile anthocyanin compositions, methods to prepare such compositions and also methods of use of such compositions to treat various afflictions. The present invention describes unique compositions of an anthocyanin and a stabilizing compound such that the combination of the two components provides that the anthocyanin does not... Agent: Omnica Gmbh

20120277174 - New macrolides and their use: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity... Agent: Basilea Pharmaceutica Ag

20120277175 - Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals: e

20120277176 - Protein arginine deiminase inhibitors as novel therapeutics for rheumatoid arthritis and cancer: In accordance with certain embodiments of the present disclosure, a self-assembling biodegradable nanoparticle is provided. The nanoparticle includes Cys-Val-Val-Val-Val-Val-Val-Lys-Lys conjugated with a synthetic polymer and has a diameter of from about 50 nm to about 150 nm.... Agent:

20120277177 - Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-beta-ribofuranosyl-1h-benzimidazole: The invention relates to novel crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.... Agent:

20120277289 - Activity generating delivery molecules: Activity-generating delivery molecules comprising the structure R3—(C═O)-Xaa-NH—R4 wherein Xaa is any D- or L-amino acid residue with a non-hydrogen, substituted or unsubstituted side chain, R3—(C═O)— and —NH—R4 are independently a long chain group, each long chain group containing one or more carbon-carbon double bonds, and salts, compositions and methods of... Agent: Marina Biotech, Inc.

20120277292 - Antisense oligonucleotides against cpla2, compositions and uses thereof: Antisense oligonucleotides against cPLA2 are provided, which are capable of inhibiting cPLA2 expression as well as superoxide production, especially in phagocytes. These antisense oligonucleotides are powerful agents for the treatment of inflammatory conditions, in particular arthritis, as well as in neurodegenerative diseases. The antisense oligonucleotides or compositions comprising the same... Agent: Mor Research Applications Ltd.

20120277286 - Compositions and methods for the treatment or prevention of mitochondrial diseases: The present invention features compositions and methods for the treatment or prevention of diseases associated with a mitochondrial defect.... Agent: The Government Of The Usa, As Represented By The Secretary, Department Of Health & Human Services

20120277285 - Control of gene expression: The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify... Agent: Commonwealth Scientific And Industrial Research Organisation

20120277283 - Localized delivery of gold nanoparticles for therapeutic and diagnostic applications: The present invention is directed to compositions and methods of localized delivery of a functionalized nanoparticle.... Agent:

20120277288 - Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification: Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the... Agent: Acuity Pharmaceuticals, Inc.

20120277287 - Modulating the cdc14b-cdh1-plk1 axis and methods for sensitizing target cells to apoptosis: The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and/or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating... Agent: New York University

20120277284 - Modulation of signal transducer and activator of transcription 3 (stat3)expression: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.... Agent:

20120277281 - Polynucleotides for medical use: s

20120277282 - Polynucleotides for use in medicine: The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and... Agent: Max-delbruck-centrum Fur Molekulare Medizin

20120277291 - Preventive for adhesion following abdominal surgery: The present inventors discovered that oligonucleotides which suppress midkine expression and antibodies which suppress midkine activity can be used to prevent post-surgical intraperitoneal adhesions.... Agent: Medical Therapies Ltd.

20120277290 - Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sex Hormone Binding Globulin (SHBG), in particular, by targeting natural antisense polynucleotides of Sex Hormone Binding Globulin (SHBG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases... Agent: Curna, Inc.

20120277293 - Immunostimulatory method: Methods for enhancing steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition who does not respond or responds poorly or inadequately to steroid anti-inflammatory treatment or a steroid dependent patient afflicted with an inflammatory condition and currently on steroid anti-inflammatory treatment who shows an inability to be... Agent:

20120277178 - Compositions and methods for treating fragile x premutation rvgg repeats-mediated toxicity: Compositions and methods of treatment or prophylaxis of fragile-X associated disorders are provided, as well as methods of screening compounds and kits to screen a library of compounds.... Agent: Emory University

20120277180 - Cofactors and methods for use for individuals: Provided herein are methods and systems for identifying one or more cofactors such as vitamins for individuals based on the genetic makeup of the individual by detecting the presence or absence of at least one genetic variant, determining a predisposition to cofactor remediable condition, generating a personalized nutritional advice plan... Agent: The Regents Of The University Of California

20120277179 - Edible energy composition: The disclosure relates to an edible energy composition that provides physical and mental benefits when ingested.... Agent: Bioclinical Development Inc.

20120277181 - Lactulose for bowel evacuation: A method of treating an adult patient in need of bowel evacuation via the administration of one or more doses of a bowel evacuant consisting of a total of from about 180 g to about 220 g of lactulose in a dosing regimen suitable to achieve bowel evacuation prior to... Agent: Cumberland Pharmaceuticals

20120277182 - Anoectochilus spp. polysaccharide extracts for stimulating growth of advantageous bacteria, stimulating release of granulocyte colony-stimulating factor, modulating t helper cell type i, and/or modulating t helper cell type ii and uses of the same: An Anoectochilus spp. polysaccharide extract for stimulating the growth of advantageous bacteria, stimulating the release of granulocyte colony-stimulating factor (G-CSF), modulating T helper cell type I (Th1 cell), and/or modulating T helper cell type II (Th2 cell) is provided. The extract comprises an effective amount of a type II arabinogalactan... Agent: China Medical University

20120277183 - Phosphate-binding chitosan and uses thereof: The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.... Agent: Cypress Pharmaceutical, Inc.

20120277184 - Blockers of pore-forming virulence factors and their use as anti-infectives: The invention provides methods for treating, delaying, and preventing pathological conditions caused by pore-forming toxins such as anthrax toxin, α-hemolysin toxin, and ε-toxin using a class of low molecular weight compounds that block the pore formed by these toxins. Specific compounds useful for treating, preventing, or delaying a disease condition... Agent: Innovative Biologics, Inc

20120277185 - Pesticidal carboxamides: e

20120277186 - Tricyclic derivatives and their pharmaceutical use and compositions:

20120277187 - Agent for preventing infection: An agent for preventing an infection with an influenza virus or a food or drink for preventing infection with an influenza virus is provided. It is the agent for preventing an infection with an influenza virus and a food or drink for preventing an infection with an influenza virus, which... Agent:

20120277190 - Prodrugs of compounds that inhibit trpv1 receptor:

20120277188 - Water-soluble benzoazepine compound and its pharmaceutical composition: wherein R represents a hydrogen atom, a hydroxy group optionally protected with a protecting group, etc., R1 represents a hydrogen atom or hydroxy-protecting group, and X represents an oxygen atom or a sulfur atom. The benzoazepine compound of the present invention and salts thereof have high solubility in water, and... Agent: Otsuka Pharmaceutical Co., Ltd.

20120277189 - Water-soluble benzoazepine compound and its pharmaceutical composition: wherein R represents a hydrogen atom, a hydroxy group optionally protected with a protecting group, etc., R1 represents a hydrogen atom or hydroxy-protecting group, and X represents an oxygen atom or a sulfur atom. The benzoazepine compound of the present invention and salts thereof have high solubility in water, and... Agent: Otsuka Pharmaceutical Co., Ltd.

20120277192 - Aminopyrimidines as syk inhibitors: The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.... Agent:

20120277191 - Forms of cidofovir: Cidofovir is obtained in different forms, including amorphous cidofovir, crystalline anhydrous cidofovir, crystalline cidofovir monohydrate, and crystalline cidofovir dihydrate, including various polymorphs.... Agent: Johnson Matthey Public Limited Company

20120277193 - Synergistic combination therapy: Combinations of compounds are provided that produce a synergistic effect when administered.... Agent: President And Fellows Of Harvard College

20120277194 - Aminopropanol derivatives: m

20120277195 - Permeation enhancers for topical formulations: A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 10-50% of Pracaxi oil, 15-40% of Patauá oil, 10-30% of Inaja oil, and 10-30% of one of more emollients.... Agent: Professional Compounding Centers Of America, Ltd.

20120277196 - Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.... Agent: Neptune Technologies & Bioressources, Inc.

20120277197 - Tigecycline formulations: The invention is directed to a frozen pharmaceutical formulation suitable for administration to a subject parenterally, comprising a therapeutically effective amount of tigecycline and an agent selected from the group consisting of lactose, dextrose, glucose, mannose, sucrose, ribose, xylose and a combination thereof, wherein the formulation in a pre-frozen state... Agent: Wyeth

20120277198 - Polyhydroxylated bile acids for treatment of biliary disorders: The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis of portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid and 3α.4α,7α,12α-tetrahydroxy-5β-cholanoic acid are disclosed, uses thereof and synthesis thereof.... Agent:

20120277199 - Modulation of gel temperature of poloxamer-containing formulations: Disclosed herein are methods for modulation of gel temperature of poloxamer-containing formulations. Also described herein are sustained release pharmaceutical formulations that gel upon contact with the body and are administered by direct application of these compositions and formulations onto or via perfusion into the targeted structure(s).... Agent: Otonomy, Inc.

20120277200 - Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction: The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.... Agent: Emotional Brain B.v.

20120277202 - Controlled release delivery system for nasal applications and methods of treatment: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma... Agent:

20120277201 - Use of hydroxyprogesterone derivatives for enhancing health and physical performance: A method for the use of derivatives of hydroxyprogesterone (17-alpha-hydroxypregn-4-ene-3,20-dione) to enhance health and physical performance in humans and more particularly to the use of hydroxyprogesterone derivatives for restoring renal hormonal balance, decreasing body weight, reducing adipose tissue, increasing endurance, promoting skeletal muscle growth, boosting androgen levels, inhibiting aromatase, and... Agent:

20120277203 - Androstenediol as an indicator for assessing estrogenicity: The present invention provides methods of determining whether a female patient will benefit from hormone replacement therapy.... Agent: The Regents Of The University Of California

20120277204 - Pyridazinone compounds: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen... Agent:

20120277208 - Benzamide compound: The present inventors have conducted studies on compounds having a GK activating action, which are promising as active ingredients of pharmaceutical compositions for the treatment of diabetes, type 2 diabetes mellitus, obesity, metabolic syndrome and related diseases caused by the aforementioned diseases, and as a result, they have confirmed that... Agent: Astellas Pharma Inc.

20120277205 - Derivatives of n-[(1h-pyrazol-1-yl)aryl]-1h-indole or 1h-indazole-3-carboxamide, preparation thereof and applications thereof in therapeutics: e

20120277207 - Novel heterocyclic acrylamides and their use as pharmaceuticals: The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.... Agent:

20120277209 - Pyrazine compounds as phosphodiesterase 10 inhibitors: or a pharmaceutically acceptable salt thereof, wherein m, n, p, R1, R2, R3, R4, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, Y and Z are defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating... Agent: Amgen Inc.

20120277206 - Reverse transcriptase inhibitors: Described herein are novel enzyme inhibitors. In some embodiments, the enzyme inhibitors are reverse transcriptase inhibitors, particularly HIV reverse transcriptase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition... Agent: Andrea Boesciences, Inc.

20120277210 - Solid dispersions containing an apoptosis-inducing agent: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises... Agent: Abbott Laboratories

20120277211 - Methods and compositions for the treatment of psychotic disorders through the identification of the sult4a1-1 haplotype: Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.... Agent: Suregene LLC

20120277212 - Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors: The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention... Agent: Domain Therapeutics

20120277213 - Ethynyl compounds: X, G, R1, R2, R3, R3′, R4, R4′, R5, R6, R6′, m, and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM)... Agent:

20120277215 - Organic compounds: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in... Agent:

20120277214 - Tricyclopyrazole derivatives: Compounds which are tricyclopyrazole derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected... Agent: Nerviano Medical Sciences S.r.l.

20120277216 - 1,2-dihydro-2-oxoquinoline compounds as 5-ht4 receptor ligands: m

20120277217 - Imidazole derivatives as ido inhibitors: Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an... Agent: Newlink Genetics Corporation

20120277220 - 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases: The present invention relates to 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives, to their preparation and to their therapeutic use.... Agent: Sanofi

20120277218 - Methods and pharmaceutical compositions for treating down syndrome: The compounds and pharmaceutical compositions of the present invention are believed to significantly inhibit Dyrk 1a activity which suggests that the agents could provide therapeutic benefit for Down syndrome, since Dyrk 1a overproduction in Down syndrome appears to account for the developmental cognitive impairment and reduction in neurogenesis. The compounds... Agent: Neuronascent, Inc.

20120277219 - Novel pyridopyrazine derivatives, process of manufacturing and uses thereof: The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.... Agent: Aeterna Zentaris Gmbh

20120277221 - Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP... Agent:

20120277222 - Treating various disorders using trkb agonists: Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C5 or C6 heteroaryl or heterocycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives... Agent: Emory University

20120277223 - Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme: v

20120277224 - Heterocyclic compounds for the inhibition of pask: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.... Agent: Bioenergenix

20120277225 - Inhibitors of bruton's tyrosine kinase: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.... Agent: Pharmacyclics, Inc.

20120277226 - Benzimidazole inhibitors of leukotriene production: s

20120277227 - Benzimidazole inhibitors of leukotriene production:

20120277228 - Novel azaheterocyclic compounds: The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.... Agent:

20120277229 - Substituted 3-(1h-benzo[d]imidazol-2-yl)-1h-indazole analogs as inhibitors of the pdk1 kinase: In one aspect, the invention relates to substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the PDK1 kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions for treating disorders associated with dysfunction of... Agent:

20120277230 - Compounds useful for treating cancer: The present invention relates to compound (I) wherein: means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a CN group, a hydroxyl group, a COOR1 group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group, a NO2 group, a... Agent: Centre National De La Recherche Scientifique

20120277231 - Quinolinyloxyphenylsulfonamides: The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or... Agent:

20120277232 - Pyridine and pyrazine derivative for the treatment of cf: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical... Agent: Novartis Ag

20120277234 - 1,2,4-oxadiazole benzoic acids: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.... Agent:

20120277233 - Pyridyl-triazine inhibitors of hedgehog signaling: The invention provides pyridyl-triazine derivatives to inhibit the hedgehog signaling pathway and the use of such compounds in the treatment of hyperproliferative diseases and angiogenisis mediated diseases.... Agent: California Capital Equity, LLC

20120277235 - Compositions for topical application having androgenic actions: e

20120277236 - Method for inhibiting mmp-9 dimerization:

20120277239 - Compositions and methods for improving night vision: The invention provides compositions and methods for improving night vision without inducing redness or significant tachyphylaxis. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine.... Agent: Alpha Synergy Development Inc.

20120277241 - Compounds, formulations, and methods for treating or preventing inflammatory skin disorders: wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms... Agent: Galderma Laboratories, Inc.

20120277237 - Novel alkynyl derivatives as modulators of metabotropic glutamate receptors: The present invention relates to novel compounds of formula I wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5... Agent: Addex Pharma Sa

20120277238 - Pharmaceutical composition containing fused hetero-ring derivative: e

20120277240 - Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes: The present invention is directed to novel substituted aminotetrahydrothiopyrans and derivatives thereof of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2... Agent: Merck Sharp & Dohme Corp.

20120277242 - Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus: Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited... Agent: Array Biopharma, Inc.

20120277243 - Pyrazolidin-3-one derivatives: o

20120277244 - Pyrazine derivatives and their use in the treatment of neurological disorders: The invention relates to novel heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.... Agent: Novartis Ag

20120277245 - Method of increasing intratumoral phe and reducing acid-mediated invasion: A method of treating cancer or inhibiting metastasis in a subject by increasing intratumoral extracellular pH is presented. The method includes administering to the subject a therapeutically effective amount of a buffer having a pKa greater than 6.1. In an advantageous embodiment the pKa of the buffer is about 7.0.... Agent: H. Lee Moffitt Cancer Center And Research Institute, Inc.

20120277246 - Use of n-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders: in which the symbols and substituents have the meaning as given herein in free form or in pharmaceutically acceptable salt form in the manufacture of a pharmaceutical composition for the treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple... Agent:

20120277247 - Novel compound useful for the treatment of degenerative and inflammatory diseases: A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or... Agent:

20120277248 - Substituted pyrrolo-pyrazole derivatives as kinase inhibitors: Substituted pyrrolo-pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with dysregulated protein kinase activity, like cancer.... Agent: Nerviano Medical Sciences S.r.l.

20120277249 - Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same: There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be... Agent:

20120277250 - Amidine-containing compounds useful as muscarinic receptor antagonists: or a pharmaceutically acceptable salt thereof, where R1-3, R5, R7, a, b, Q, X, X′, X″, Y, Z, and Ar are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also relates to pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of... Agent: Theravance, Inc.

20120277251 - Analogs of dehydrophenylahistins and their therapeutic use:

20120277252 - Antibacterial agents and methods of use thereof: The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial... Agent:

20120277253 - Subcutaneous paliperidone composition: The present invention relates to pharmaceutical composition for subcutaneous injection comprising a paliperidone compound wherein the composition releases the paliperidone with an immediate onset of action and continuously for at least 3 weeks, and wherein the composition has a pharmacokinetic profile in vivo with substantially no burst release of the... Agent:

20120277254 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120277255 - Inhibitors of bruton's tyrosine kinase: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.... Agent: Pharmacyclics, Inc.

20120277257 - Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms: Disclosed herein are methods of treating diseases and disorders responsive to inhibition of Hsp90, pharmaceutical compositions, pharmaceutical dosage forms and medicaments useful for the treatment of diseases responsive to inhibition of Hsp90, and methods of making the pharmaceutical compositions, pharmaceutical dosage forms and medicaments.... Agent: Myrexis, Inc.

20120277256 - Frequency modulated drug delivery (fmdd): Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety... Agent: Synthonics, Inc.

20120277258 - Chemical compounds: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.... Agent:

20120277259 - Substituted benzofused derivatives and their use as vanilloid receptor ligands: The present invention relates to substituted benzofused derivatives, which can be used as vanilloid receptor ligands, method of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.... Agent: Glenmark Pharmaceuticals S.a.

20120277260 - Use of methylnaltrexone and related compounds to treat constipation in chronic opioid users: A method of preventing or treating constipation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with... Agent: The University Of Chicago

20120277262 - New aminotetraline derivatives: The present application relates to compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds in producing medicaments for the treatment of various diseases and conditions, such as of the central nervous... Agent:

20120277261 - Pharmaceutical formulations useful in the treatment of insomnia: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable... Agent: Orexo Ab

20120277263 - Polymorphs of 1-cyclopropyl-7-([s,s])-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro -8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof: e

20120277264 - Antithrombotic agent: An object of the present invention is to provide an antithrombotic agent that has fewer side effects and that is highly effective. The present invention provides an antithrombotic agent comprising (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium p-toluenesulfonate represented by Formula (1) as an active ingredient.... Agent: Tokai University Educational System

20120277265 - Novel polyquinoline derivatives and the therapeutic use thereof: The invention relates to a method for chelating metal ion and/or dissolving amyloid aggregates, including chelating metal ions and/or dissolving amyloid aggregates with a compound of formula (I):... Agent: Palumed S.a.

20120277266 - Hepatitis c virus inhibitors: This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV... Agent: Bristol-myers Squibb Company

20120277267 - Method of managing or treating pain: A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative... Agent: Archimedes Development Limited

20120277269 - Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.... Agent: Boehringer Ingelheim International Gmbh

20120277268 - Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid: The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith.... Agent: Vertex Pharmaceuticals Incorporated

20120277270 - Method for decreasing symptoms of alcohol consumption: The present invention relates to methods and compositions of metadoxine and physiologically compatible active derivatives thereof, and their use for decreasing symptoms of alcohol consumption as well as in the prevention of alcohol consumption related symptoms in subjects in need thereof.... Agent: Alcobra Ltd.

20120277271 - Methods and compositions: The present invention relates generally to the field of pain management, and in particular, the management of neuropathic or inflammatory pain including a neuropathic or inflammatory component of nociceptive pain. More particularly, the present invention provides methods and compositions which treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of... Agent: Relevare Aust. Pty Ltd

20120277272 - Ethanamine compounds and methods of using the same: (S)-2-methyl-1-phenyl-2-(pyridin-2-yl)propan-1-amine, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, uses of said compound or salt for therapy of depression and other conditions, and methods of treating depression and other conditions by administering said compound or salt.... Agent: Astrazeneca Ab

20120277273 - Small molecule inhibitors of rgs proteins: The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).... Agent: The Regents Of The University Of Michigan

20120277274 - Epothilone compound formulations: The present application relates to compositions for parenteral administration of epothilone compounds, such as ixabepilone.... Agent:

20120277275 - Azole and thiazole derivatives and their use: Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiratory tract diseases:... Agent: Pulmagen Therapeutics (synergy) Limited

20120277276 - Treatment of edible crops: In the growing of crops for consumption, a method for the removal of pathogens includes the addition to irrigation water for the crops of an anti-pathogen composition and supplying the anti-pathogen composition to the crops prior to harvest while normal irrigation is effected. The anti-pathogen composition is based on halogens,... Agent:

20120277277 - Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal: Disclosed are methods for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals, comprising administering to a mammal in heed thereof a pharmaceutical composition comprising 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an anti-tumour agent or in combination with radiation... Agent: Array Biopharma Inc.

20120277278 - Phenylbutazone carrier formulation showing increased bioactivity in animals: An improved phenylbutazone carrier composition provides increased palatability to horses. Additionally, the composition improves the bioavailability of the phenylbutazone and thus increases the horse's blood plasma levels of the medicine for the same effective dosage of the medicine.... Agent:

20120277279 - Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions:

20120277280 - Phenoxy-pyrrolidine derivative and its use and compositions: The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound.... Agent: Medicis Pharmaceutical Corporation

20120277294 - Functional food additives: Novel compounds, and in particular to diacylglycerol (1,3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional food additives. These may for example be used as nutraceuticals and/or pharmaceuticals in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress and... Agent:

20120277295 - Kit for cancer treatment and pharmaceutical composition for cancer treatment: v

20120277296 - Selective cb2 receptor agonists for use in the prevention or treatment of alcoholic liver disease: The present invention relates to selective CB2 agonists for use in the prevention or treatment of alcoholic liver disease and particularly alcoholic hepatic steatosis and liver inflammation, and pharmaceutical composition thereof.... Agent:

20120277297 - Pharmaceutical composition useful as acetylcholinesterase inhibitors: The present invention relates to pharmaceutical composition comprising the naturally occurring compounds selected from (±) Marrnesin, Columbianetin, Dihydroxanthyletin and substituted coumarin derivatives of 7-allyloxy coumarin, 7-benzyloxy coumarin, 7 -methoxycoumarin, 7-acetyloxy coumarin, 4-methyl-7-hydroxy coumarin and 4-methyl-7-acetyloxy coumarin. The said compositions possess a high degree of acetylcholinesterase inhibitory (AChE) property.... Agent: Council Of Scientific And Industrial Research

20120277301 - Chroman-derived anti-androgens for treatment of androgen mediated disorders: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.... Agent: Wisconsin Alumni Research Foundation

20120277300 - Compositions and methods for inducing bone growth and inhibiting bone loss: Compositions useful for inducing bone growth or inhibiting bone loss in an animal comprising one or more isoflavones or isoflavone metabolites and methods for inducing bone growth or inhibiting bone loss in an animal utilizing such compositions. The compositions and methods are particularly useful for post-menopause, post-andropause, gonadectomized, spayed, or... Agent:

20120277302 - Equol-containing fermentation product of soybean embryonic axis, and method for production thereof: m

20120277303 - Equol-containing fermentation product of soybean embryonic axis, and method for production thereof:

20120277298 - Flavanones-containing food compositions: The present invention relates to food products comprising flavanones. In particular, it relates to food products comprising hesperidin having improved stability. The present invention also concerns processes for the manufacturing of food products comprising said flavanones, especially hesperidin and to the use of the food products in the manufacture of... Agent: Nestec S.a.

20120277299 - Method for modulating ion transporter: The present invention relates to a method for modulating ion transporter or treating disturbances of electrolyte transport during disease state, comprising an administration at a fatty acid derivative to a mammalian subject. The present invention also relates to a composition for modulating ion transporter or treating disturbances of electrolyte transport... Agent: Sucampo Ag

20120277304 - Sodium transhinone iia sulfonate hydrate and preparation method and use thereof: The present invention relates to sodium tanshinone IIA sulfonate hydrates as well as preparation methods and uses thereof. The sodium tanshinone IIA sulfonate hydrates have molecular formula of C19H17NaO6S.nH2O, wherein n=0.5-4.0. The sodium tanshinone IIA sulfonate hydrates of the present invention have better storage stability than anhydrous sodium tanshinone IIA... Agent:

20120277305 - Fatty acid guanidine and salicylate guanidine derivatives and their uses: The invention relates to fatty acid guanidine or salicylate guanidine derivatives; compositions comprising an effective amount of a fatty acid guanidine or salicylate guanidine derivative; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid guanidine or salicylate guanidine derivative.... Agent: Catabasis Pharmaceuticals, Inc.

20120277306 - Composition containing metal-acidic amino acid chelate accelerating absorption of metal: Provided is a method for treating prostate and/or testicular disease, comprising: administering a pharmaceutical composition comprising a zinc-aspartate chelate as an active ingredient to a subject in need thereof, wherein the prostate disease is selected from the group consisting of prostatitis, enlargement of prostate and prostate cancer. The composition for... Agent:

20120277307 - Method for treating osteoarthritis: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more... Agent:

20120277308 - compounds for treating cancer and other diseases: This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an... Agent: Pacific Arrow Limited

20120277309 - Methods of controlling venous irritation associated with the treatment of a cardiac disorder: A pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate in a concentration between about 75 mM and about 150 mM, which is substantially free of the R-isomer or pharmaceutically acceptable salt thereof, is provided. A method of treating a cardiac disorder is also provided and includes administering to a subject in need thereof a... Agent: Baxter International Inc.

20120277310 - Novel conjugates for treating neurodegenerative diseases and disorders: A conjugate comprising L-DOPA covalently linked to at least one γ-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder.... Agent: Ramot At Tel-aviv University Ltd.

20120277311 - Lipoxin compounds and their use in treating cell proliferative disorders: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.... Agent: The Brigham And Women's Hospital , Inc.

20120277314 - catheter lock solution comprising citrate and a paraben: This invention relates to compositions, methods, devices and kits relating to the infusion of a catheter lock solution into an indwelling catheter. Inventive compositions, methods, devices and kits aid in diminishing the effects of microbial infection in catheters and occlusion of the catheters. A lock solution provided by the invention... Agent: Ash Access Technology Inc.

20120277313 - Cosmetic composition stabilized higher oily part: The present invention relates to a cosmetic composition having a high content of a stable oil phase, and more particularly to a cosmetic composition, which combines advantages of spreadability and softness of an oil-in-water type with emollient effect and water resistance of a water-in-oil type as a resulting of stabilizing,... Agent:

20120277312 - Ethylgallate and related compounds as a treatment for sepsis and septic shock: The use of ethyl gallate methyl gallate or 3,4-dihydroxybenzoate for treatment of septic shock Said compounds may also prophylactically treat septic shock via administration to a subject before the development of a fall in blood pressure.... Agent:

20120277315 - Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors: A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.... Agent:

20120277316 - Methods and compositions for treating and preventing parenteral nutrition associated liver disease: Methods and compositions for treating or preventing parenteral nutrition associated liver disease are provided. Methods and compositions for advancing enteral tolerance in subjects receiving enteral nutrition are provided. The methods involve the use of omega-3 fatty acid compositions. In some embodiments the omega-3 fatty acid compositions comprise docosahexanoic acid and... Agent: University Of Tennesse Research Foundation A University

20120277317 - Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases: A method for the treatment and/or prevention of amyloidos-related diseases, such as for example Alzheimer's disease and IgA nephropathy, comprising administering to a human or an animal a composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) is provided.... Agent: Pronova Biocare As.

20120277318 - Non-steroidal anti-inflammatory drugs for cough: The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs.... Agent: Bayer Intellectual Property Gmbh

20120277319 - Use of tapentadol for inhibiting and/or treating depression and anxiety: The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety.... Agent: Gruenenthal Gmbh

20120277320 - Inhibition of the survival of skin cancer by cyclohexenone compounds from antrodia camphorata: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of skin cancer cells and be used as a pharmaceutical composition to inhibit the skin... Agent: Golden Biotechnology Corporation

20120277321 - Method for preparing a composition comprising a compound based on vanillin and ethyl vanillin, resulting composition and uses thereof: A method for preparing a composition including a compound based on vanillin and ethyl vanillin is described. A resulting composition and uses thereof in many fields of application, in particular in human and animal food is also described. A method for preparing a composition including a compound based on vanillin... Agent:

20120277322 - Process for bacterial stabilizing of aqueous ground natural calcium carbonate and/or precipitated calcium carbonate and/or dolomite and/or surface-reacted calcium carbonate-comprising mineral preparations: This invention discloses a process for stabilising an aqueous mineral preparation comprising a step of adding at least one aldehyde-containing and/or aldehyde-releasing and/or phenolic and/or isothiazoline biocide to said aqueous mineral preparation.... Agent:

20120277323 - Cellulose capsules and methods for making them: Disclosed are cellulose capsules, methods for preparing a cellulose capsule, and compositions comprising cellulose capsules, including sustained- or controlled-release dosage forms comprising cellulose capsules.... Agent: University Of Iowa Research Foundation

20120277324 - Betaine esters and process for making and using: A variety of betaine esters, including dial kylaminoalkyl cocoate betaines. These betaines were advantageously prepared in high yield and purity by a three-step chemoenzymatic process. These betaine esters have excellent surfactant properties.... Agent: Eastman Chemical Company

20120277325 - Novel pyrimidine derivatives and their use in perfume compositions: v

20120277326 - Biomarkers of cancer: Methods for diagnosis and staging of ovarian cancer, based on relative immunoreactivity of different IgG subclasses of autoantibodies, autoantibodies to defined antigens, e.g., antigens with specific subcellular localization, are described.... Agent:

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140710: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.67342 seconds

PATENT INFO